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Abstract:
The studies in this thesis were designed to elucidate the role of clinical and 
endocrinological factors in the growth suppression that is a recognised 
feature of chronic renal failure (CRF) and renal transplantation, and to 
determine whether the mechanism of action of recombinant growth hormone 
(rhGH) is by improving endocrine disturbances or via a direct anabolic effect.
Endocrine parameters (IGF-I, IGF-II, IGF bioactivity, IGFBP-1, IGFBP-2, 
IGFBP-3, ALS, insulin and c-peptide) were studied in 3 groups of children - 
those with renal transplants and those with reduced glomerular filtration rate 
(GFR), moderate and severe. Clinical variables (age, gender, body mass 
index - BMI), aetiology of renal failure, steroid dose and renal modality -  
(CRF/ transplant/ dialysis) were also included in the analysis. All 3 groups 
had elevated mean IGF-II, IGFBP-2 and -3 levels. IGF-I levels, although in 
the normal range, would be considered low in this population as GH levels are 
elevated. IGF-II and ALS had a significant positive influence on growth, whilst 
renal modality, age, steroid treatment and duration of dialysis all had a 
significantly negative effect. Collectively these parameters explained 38.4% of 
the variability in height (Ht) standard deviation score (SDS) in the population 
studied. Of all the parameters studied, only transplantation had a significant 
influence on Ht velocity (Vel) SDS. This was positive and accounted for 26%  
of the variability in Ht Vel SDS.
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Protein turnover was measured in 8 fasting children (4 CRF, 4 transplant) 
using stable isotopes (13C) incorporated into leucine. Turnover was lower at 
baseline, and remained so despite any increases with rhGH treatment, in 
transplanted children compared with those with CRF. The body mass index of 
transplanted children who were on steroid treatment was higher, but their 
resting energy expenditure (REE) was lower than CRF patients. RhGH 
improved growth rate, arm muscle area and REE significantly whilst fat area 
decreased. C-peptide and IGFBP-3 showed a more consistent increase than 
IGF-I whilst IGFBP-1 decreased with rhGH.
The studied parameters can only partially explain the observed variability in 
growth rate suggesting the involvement of other factors. RhGH has anabolic 
effects which are apparent despite variation in endocrine responses between 
individuals. This variation could be attributed to differing levels of resistance to 
the actions of hormones.
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Chapter 1
Introduction
Introduction
1.1 Normal growth and influencing factors
The general inference of the term “ growth” is of linear increase in length. 
As the visual result of a complex process, it provides an easy method of 
documenting change and progress that reflects general health (1, 2). 
Growth however also encompasses an increase in body weight and size 
of the organs (1). It is a dynamic process that varies on a daily basis, 
and has a seasonal preponderance as well (3, 4). The velocity of growth 
differs at various ages, and has a predominantly biphasic pattern in life 
as it is most rapid in the first two years of life and during puberty, 
although a gradual deceleration in the former phase that continues until 
puberty can be noted (4). The linear accruement of height ceases with 
closure of the epiphysis at the end of puberty. Growth is determined by 
genetic and environmental influences. Genetic influences may lead 
directly to hormonal deficiencies, imbalances or insensitivity as in Growth 
Hormone (GH) Insensitivity Syndrome (Laron Dwarfism) (5), or affect the 
development of organs such as the kidneys leading to chronic illnesses. 
Environmental factors encompass nutrition, acquired illnesses, 
particularly those with long term consequences, and psychological
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deprivation. The association between parental and offspring height is 
well documented.
Ethnic differences in growth and development are recognised (1, 6). 
Seasonal variations are also detectable in the growth pattern (7).
With increasing knowledge of growth disorders, it is becoming apparent 
that the common pathway for the above factors to influence growth is via 
the endocrine system, and therefore it is important to understand the 
normal growth pattern in order to manage abnormalities.
1.1.1 Normal growth
Growth is most rapid in utero, when the fertilised zygote increases 
tremendously in size, and then starts to decline rapidly after birth, over 
the next three years. Apart from a slight acceleration in mid-childhood, 
growth velocity shows a steady decline until the pubertal growth spurt 
takes place. Most rapid growth, therefore, takes place during early 
childhood and at puberty, although the former stage is a gradual 
deceleration of the growth rate continuing throughout childhood until 
puberty.
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In 1759 Count Phillip DeMontbeillard started to plot his son’s height, and 
produced the first chart that recorded growth velocity (figure 1.1) (7). In 
1965 Tanner and Whitehouse carried out a survey of the heights and 
weights of healthy Caucasian school children in the SE of England and 
especially the London area, and plotted the normative data obtained to 
produce reference curves from the distribution of these measures (8,9). 
Due to secular increases in size and earlier maturity, new height and 
weight reference curves were produced based on national data obtained 
between 1978-1990 (10). Data from non-white children was excluded 
due to ethnic differences in size.
Using reference charts, it can be determined whether a child’s growth is 
of concern. Height and weight have a normal distribution, and most 
children’s auxology can be plotted on these curves. Using parental 
height (cm), a target height range can be derived using the following 
equation:
Target height range (cm) = mean of parental height (cm) ± 8.5 cm
where the mean of parental height has been adjusted for the sex of the 
child by adding 13cm to the maternal height for male children, or 
subtracting 13 cm from the paternal height for female children to obtain 
the mid-parental centile. Using the chronological age of the child, height
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and bone age, assuming the child maintains the existing rate of growth, 
an adult height can be predicted (11,12) and compared to the target 
height derived from the parental heights. Concern arises if the predicted 
height lies outside the parental target range, or below 3rd centile 
reference curve or, more unusually, above the 97th centile reference 
curve (7). Further information can be obtained from monitoring rate of 
growth or height velocity. This may fluctuate during the year, and from 
year to year. For accuracy it is advisable to leave a minimum gap of 6 
months between measurements in order to determine velocity over a 
year, although velocity over 12 months provides the greatest accuracy. 
Records of velocity show that there is no correlation in successive years, 
with oscillations around the 50th centile in normal children. Data must be 
interpreted in the context of the child’s maturity. A persistently high or low 
rate of growth will alter the height of the child, and velocities constantly 
below the 25th centile will result in short stature and are regarded as 
abnormal (7).
Variations of normal growth due to genetic influences can be observed. 
A striking example of this is the difference in height observed between, 
and indeed within, various ethnic groups (13). Environmental factors 
such as nutrition and exercise contribute significantly to growth as well 
(1). The level of contribution of genetic and environmental influences 
cannot be apportioned at present, with secular changes observed in 
growth trends in subsequent generations and with migration (14).
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Abnormalities in growth can also arise from genetic and environmental 
influences. Ill health can occur due to genetic and/or environmental 
factors, and will interfere with growth, which may show “catch up” with an 
increased velocity in the recovery period, especially when the illness 
occurs during the phase of slower growth (15). Chronic illness leads to a 
more complex picture as the disruption maybe complete (cessation of 
growth) or incomplete (slowing of growth rate), the overall impact of 
which is dependent on the phase of growth during which the worst effects 
of the illness are experienced and the duration of illness. Chronic illness 
can lead to alterations in the normal physiological and biochemical 
processes of the body, particularly puberty (16,17). Poor growth may be 
the only manifestation of underlying illness (18). The growth suppression 
present may appear disproportionate to the degree of illness, and one 
thought on this is that this maybe a survival mechanism for the body to 
diminish “non-essential metabolic” functions (19). Delayed and poor 
pubertal progression may also be a manifestation of this adaptation.
Growth in chronic renal failure (CRF) has evoked interest as survival 
rates and life expectancy have improved. The number of children under 2 
starting renal replacement therapy in Europe has doubled over 15 years 
(20), whilst in N. America 21% of children who receive renal transplants 
are under 6 years of age (21), highlighting the need to focus on the 
quality of life of these patients. The aetiology of CRF can be attributed to
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either genetic and/or environmental influences. The complications 
arising secondary to the CRF such as anorexia, uraemia (22), acidosis 
(23), hormonal imbalances (19) and anaemia (24) all contribute to the 
poor growth observed.
1.2 Chronic renal failure and growth
1.2.1 Chronic Renal Failure
CRF is signified by reduced glomerular filtration rate (GFR)- ranging from 
mild failure (40-60 mis min'11.73 m2 ); moderate (20 - 40 mis min'1
1.73 m2); severe (<20 mis min'11.73 m2) and end-stage (<10 mis min'
11.73 m2). End stage renal failure (ESRD/ ESRF) necessitates the 
introduction of supportive measures such as dialysis or, if possible, renal 
transplantation. The latter increases quality of life and life expectancy
(25).
1.2.2 Growth in children with chronic renal failure
Congenital abnormalities are the commonest cause of CRF in childhood
(26), and those with congenital renal dysplasia may have reduced birth 
weight (27, 28).
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Reduction in GFR leads to rise in creatinine. A rise of 1mg/dl (90 
|nmol/ml) is associated with a decrease of -0.15 SDS in height (29). Vast 
improvements in the conservative management of complications arising 
secondary to CRF such as poor nutritional status, acidosis, bone 
disease, and anaemia have taken place in the last 10-15 years, and are 
associated with improvements in growth rate (30, 28). More invasive 
measures, in the form of dialysis and renal transplantation, are required 
as end-stage renal failure approaches.
Transplantation has had a radical impact on the quality of patients’ lives, 
and patients can go on to lead normal lives, including having children 
(31). A retrospective study looked at the outcome of 150 children who 
had received renal transplants between 1970 to 1993. Adult height was 
available for 100 of these. Eighty-four adults had non cystinotic disease 
and 37 of these, and all 16 with cystinosis, had growth stunting with a 
final height less than -2 SDS below the mean (31). Children who receive 
a transplant between the ages of 2- 5 years show catch-up growth, but 
this trend decreases as age at transplantation increases (29). Other than 
age at which transplantation takes place, use of immunosuppression 
(particularly steroids), pre-transplantation dialysis treatment, graft 
function, mildness of growth retardation pre-transplantation and number 
of transplants are factors adversely associated with growth post 
transplantation (32, 29, 33).
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CRF can occur at any age from birth onwards. Foetal manifestations of 
CRF can be limited to oligohydramnios and its complications, due to 
placental replacement for the kidney in utero. Many infants are now 
diagnosed antenatally using ultrasound. However there is evidence that 
congenital renal disease results in lower birth weight (30). Children with 
congenital renal disease are particularly vulnerable to growth stunting as 
a direct effect of the illness at a time of rapid growth, and lack of 
appropriate management in non-specialist centres especially with regard 
to nutrition (27).
The aetiology of CRF can be variable, from infection (haemolytic uremic 
syndrome, sepsis), glomerulonephritis, secondary to drug usage 
(chemotherapy, antibiotics), genetic (nephronophthisis, polycystic 
kidneys, glomerulopathies), or malignancy. However the commonest 
cause of CRF in childhood is congenital renal dysplasia with or without 
reflux or obstruction (26).
The increase in the numbers of children with early onset CRF surviving to 
adulthood has highlighted the effects of the illness on growth and 
nutrition. Retrospective studies carried out in 1995 showed that the mean 
final adult height of males was -1.98 SDS and -1.41 SDS for females 
(34). In 1974 Chantler demonstrated, using animal models, that rats 
rendered uremic by 5/6 nephrectomy were smaller, and weighed less 
than controls (35). Kleinknecht et al in 1983 noted from their prospective
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study that significant deceleration of growth velocity occurred within the 
first two years of life in children developing CRF in infancy, resulting in 
short stature, despite normalisation of the growth velocity in subsequent 
years (28). This has been confirmed by other studies (30). Catch up 
growth, reflected by growth velocity rate above that of age related peers, 
to compensate for the loss during the maximal growth period is rarely 
observed.
Since the early eighties, significant improvement in the therapeutic 
management of CRF has taken place. Knowledge of the importance of 
adequate nutritional status, not only in CRF (36, 37, 38), but any chronic 
disease, has increased (39). This is true not only in children (38), but also 
for adults (40). Multinational, cross sectional studies have shown that 
adult patients with ESRD manifest protein calorie malnutrition typified by 
reduced body weight, skin fold thickness and mid arm circumference
(41). Severe malnutrition as characterised by decreased serum albumin 
levels is associated with higher mortality rates (42). In children, poor 
growth can be a manifestation of malnutrition (1). Supplementation of 
calories to 120% of daily requirements has been shown to slow the rate 
of decrease of height velocity and improve weight gain in infants with 
chronic renal failure (30). This improvement in Ht SDS, although greater 
in supplemented children with mild rather than severe CRF, and better in 
those supplemented compared to non-supplemented with the same 
degree of CRF, still remains below that of normal controls (30).
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Despite supportive measures such as dialysis, other complications such 
as acidosis, bone disease (43), and anaemia can occur. These can be 
present, albeit in a milder form, when CRF is established, increasing in 
severity with progressive deterioration in GFR (43). Improvements in the 
management of CRF aim to identify and prevent or minimise the onset 
and progression of complications. It is also important to bear in mind that 
both dialysis and transplantation are associated with their own 
complications.
1.2.2.1 Acidosis
Acidosis is a complication of reduced GFR, and many patients with CRF 
require bicarbonate supplementation. Studies have shown that reduced 
serum bicarbonate is associated with decreased GH secretion and 
weight gain in rats (44), neonates (45, 46) and in healthy volunteers 
rendered acidotic (47). Protein catabolism is also higher (48, 49) and 
exogenous recombinant growth hormone (rhGH) less effective in 
improving the rate of growth (50) in acidotic states.
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1.2.2.2 Anaemia
Anaemia occurs a complication of CRF, secondary to decreased 
erythropoietin (51), leading to reduced exercise tolerance, impaired 
cardiac function and insufficient tissue oxygenation. Replacement 
therapy is administered to correct the anaemia with improvements in 
growth (24).
1.2.2.3 Renal osteodystrophy
Phosphate retention, hypocalcaemia and hyperparathyroidism lead to 
renal osteodystrophy (52). Bone disease arises partly from the electrolyte 
abnormalities present in CRF secondary to the reduced GFR, but also 
due to the loss or diminished action of the kidney 1 oc-hydroxylase in the 
conversion of 25 (OH) D3 to its active metabolite 1,25 (OH)2 D3 , which 
enhances calcium resorption from the renal tubules, absorption from the 
gastrointestinal tract and increases the action of osteoblasts and 
osteoclasts (53). Hypocalcaemia leads to hyperparathyroidism (54). 
Treatment is by dietary phosphate restriction, phosphate binders and the 
prescription of activated vitamin D. However the effect of renal 
osteodystrophy on growth in CRF is controversial (55).
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1.2.2.4 Dialysis and renal transplantation
ESRD necessitates the commencement of dialysis or renal 
transplantation. Malnutrition and growth suppression are maximal in 
ESRD (56). Some improvement may be demonstrated with the 
commencement of peritoneal dialysis compared to the immediate 
predialysis phase in height standard deviation score (Ht SDS) as 
observed over a six month period (57). The growth of children on 
continuous ambulatory peritoneal dialysis is better than those on 
haemodialysis (57, 56). However, dialysis is an invasive process and 
increases the risk of infection in a patient group with an already 
compromised immune function (41), thus compounding the problems 
with malnutrition and growth. The other complications described above 
are maximal in this group, leading to increased morbidity and mortality
(42).
Transplantation results in an improvement in nutrition, growth and 
general well-being. The height at the time of transplant, GFR after 
transplant (if < or > 50 mls/min/1.72m2) (59) and age at time of 
transplant (32) are important determinants of progress in growth after 
transplantation, and a positive association is observed with higher values 
of the former two, whilst the optimal age of the latter for catch-up growth
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is between 2-5 years. Immunosuppressive medication such as 
glucocorticoids used following the transplant to prevent organ rejection 
also has a detrimental effect on growth (60).
1.2.3 Endocrine factors in CRF
Despite preventing or minimising the above factors, children with CRF 
still demonstrate problems with growth (30). This has lead to more 
detailed attention to endocrine factors in CRF. Initial findings showed 
normal or elevated growth hormone (GH) levels, but closer scrutiny has 
revealed insensitivity to the actions of GH (61, 62), and abnormalities of 
the GH-insulin-like growth factor (IGF) axis (63, 64). (See Chapter 3).
1.2.4 Relevance of bone age in CRF
Bone age in chronic illnesses, particularly in CRF can be unreliable as 
the bone architecture can be altered by renal osteodystrophy (65). This 
can also occur in a population with use of steroids following renal 
transplantation (65). Therefore bone age in CRF is not a helpful 
measurement (65).
33
1.3 Consequences of short stature
Studies have demonstrated that adults with short stature have low self­
esteem (66), but children with CRF do not appear to have a major 
preoccupation with growth although this becomes more of a problem 
with increasing age (67). This may be due to the limited awareness 
children have of life experiences. Children appear to be more concerned 
about the impact of their illness on other areas of their life, particularly 
their family (67). Parents of these children also place more emphasis on 
future health rather than growth (67).
1.4 Recombinant human growth hormone
Use of rhGH and trials of recombinant IGF-I (rhIGF-l) in GH deficiency, 
GH resistance and chronic illnesses have been closely monitored for 
efficacy and safety. This has increased knowledge of the benefits of 
rhGH in areas other than linear growth alone. RhGH has been effective 
in improving lean body mass, affect and in some reports cardiovascular 
function in adult GH deficient patients (68). It also appears to be 
beneficial in osteoporotic bone disease (69). Some of these benefits 
have been clearly demonstrated in GH deficient children (70). Attention 
has therefore been focused on how rhGH can be of benefit to children 
with CRF and those subjected to prolonged steroid therapy. Data on final
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height of short children with CRF following use of rhGH therapy is now 
emerging and shows that response of individuals can vary (71, 72).
1.4.1 Indications for GH therapy
It has been accepted since the fifties that replacement therapy for GH 
deficiency is required. About 25 years ago, GH therapy was restricted to 
replacement in GH deficiency due to the limited availability and expense 
of GH as it was obtained from the pituitaries of cadavers. With DNA 
technology, it became possible to mass produce recombinant GH (rhGH) 
which was more cost effective and safer. RhGH is now licensed for use 
in CRF and in girls’ with Turner’s Syndrome, in addition to GH deficiency.
Some centres have also used rhGH in the treatment of children with 
idiopathic short stature with some improvement in growth rate (73), and 
although preliminary data on final height appears promising (74) there is 
still controversy regarding use of rhGH in these children. It is now 
accepted that adults with GH deficiency benefit from replacement 
therapy (68).
Adolescents are capable of giving informed consent, and rarely withhold 
this for rhGH although compliance may then become an issue. Younger 
children commence rhGH on the basis of consent provided by parents.
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1.4.2 Recombinant growth hormone in children with CRF 
and renal transplant
RhGH is effective in children with CRF and those post renal 
transplantation and preliminary data of its influence on final height 
appears promising (72,75), but is limited. RhGH is used in 
supraphysiological doses in CRF (4 iu/m2/day or 0.07 mg/kg/day). It is 
not clear whether protein kinetics in children with CRF are altered with 
increase of catabolism, decrease of synthesis or a combination of the 
two. RhGH has an anabolic effect on lean body mass which maybe direct 
or by stimulation of its intermediaries, particularly IGF-I.
1.5 Nature of work for MD thesis
The work for this MD has involved children with CRF, ESRD, post renal 
transplant, and for comparison, children on steroid treatment for 
nephrotic syndrome or vasculitis without current renal involvement.
Multiregression analysis has been applied to determine which 
parameters of clinical and endocrinological origin have a significant 
influence on the Ht SDS of all the children and Ht Vel SDS of prepubertal 
children. Protein turnover in short children, an area that has been 
studied little in children, particularly in those with renal impairment, was
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determined before and after the commencement of rhGH and interpreted 
in the context of hormonal involvement.
1.5.1 Hypotheses
I. Levels of endocrine factors comprising the GH-IGF-IGFBP axis 
and their importance to growth are altered by deteriorating GFR 
and steroid usage and this will influence the Ht SDS and Ht Vel 
SDS of patients with CRF, ESRD and renal transplants.
II. Use of rhGH in children with CRF and renal transplants will 
improve growth, lean body mass, reduce adipose tissue and 
increase protein turnover that maybe reduced compared to 
healthy individuals.
1.5.2 Aims of the work for this thesis
I. To study children with CRF, ESRD treated with dialysis and post 
renal transplant with or without growth retardation, to determine 
which clinical and endocrinological (GH-IGF-IGFBP axis) 
parameters are important to growth.
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II. To study protein turnover in children with CRF and those with a 
renal transplant, and study the effects of rhGH therapy on protein 
turnover, growth and endocrine factors.
1.6 Ethical approval
Ethical approval for all the studies in the thesis was granted by the Ethics 
Committee at Great Ormond Street Hospital.
Written informed consent was obtained from the parents, and when 
appropriate from the children.
Clearance for use of stable isotopes was obtained from the dangerous 
drugs and therapeutics committee.
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Chapter 2
Patients
Patients
2.1 Introduction
This chapter provides details of the principal epidemiological and clinical 
features of the children recruited for the studies described in this thesis 
in subsequent chapters. Studies undertaken on the children had both 
clinical and laboratory aspects.
2.2 Growth and the Growth-Hormone-lnsulin-like 
Growth Factor axis
2.2.1 Patients
Patients for this study were recruited on the basis of their renal status of 
which there were four categories: chronic renal failure (CRF), end-stage 
renal disease (ESRD) necessitating dialysis support, renal transplant 
and those with a normal glomerular function (GFR) -  but on steroid 
treatment.
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Criteria for recruitment were
i) None of the children were acutely unwell (pyrexia!, septic or 
being treated for acute transplant rejection).
ii) None of the children were on recombinant growth hormone 
therapy.
iii) Children on steroid therapy had not received steroids at a 
dosage > 1mg/kg/day in the fortnight prior to sample collection.
iv) Children with a history of proteinuria did not have more than 1 + 
on dipstick testing of their urine on the morning of sample 
collection, nor had they had more than 2+ intermittently in the 
fortnight prior to sample collection.
v) All patients with CRF had a GFR less than 40ml/min/1.73m2.
vi) Children were able to fast for the study as required, and if on 
overnight nasogastric tube feeds, parents were amenable to 
stopping the feed at least 6 hours prior to the sample collection 
time which was usually at or soon after 9.00 am.
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2.2.1.1 Chronic renal failure group (appendix 2.1)
Thirty one children (7 females) with CRF aged (mean ± SD) 11.7 ± 3.6 
years were recruited. Patient demographics are as detailed in appendix 
2.1, and table 2.1 .
2.2.1.1.1 Primary diagnosis
Fourteen children had congenital renal dysplasia (8 also had 
vesicoureteric reflux - VUR). Four had posterior urethral valves, 4 had 
autosomal recessive polycystic kidney disease (ARPKD), 2 had focal 
segmental glomerulosclerosis (FSGS), 2 had acquired CRF (birth 
asphyxia, post cardiac surgery), 1 had CRF of unknown cause, 1 had a 
remnant kidney after treatment for Wilm’s tumour, 1 had Alport’s 
syndrome, 1 had VATERs syndrome and 1 had cystinosis.
2.2.1.1.2 Pubertal status and auxology
The pubertal status (mean ± SD) of the children was 2 ± 1. There were 
15 children who had commenced pubertal development. Of these 4 had 
pubertal delay (pubertal stage below 3rd centile for genital/ breast 
development for age determined using age and gender appropriate
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Tanner and Whitehouse centile charts for pubertal development). Two 
females were pre-pubertal (stage 1) at 12.5 and 13 years and thus would 
also be considered as delayed.
Mean ± SD auxological parameters of all the children were as follows-: 
body mass index (BMI) standard deviation score (SDS) 0 ± 1.2, Height 
(Ht) SDS -1.4 ± 1.5, Ht velocity (Vel) SDS -0.4 ± 3.4, and weight (Wt) 
SDS -0.9 ± 1.7. Of these children, ten had a Ht SDS < - 2.0 SDS.
2.2.1.1.3 Renal function and acid-base status.
The mean (SD) glomerular filtration rate (GFR) of the patients was 22.5 ±
7.4 mls/min/1.73 m2. The total body carbon dioxide (TC02), a measure 
of the acid-base status of the children, was 22.9 ± 3.3 mmol/l (normal 
range 20 to 26 mmol/l).
2.2.1.1.4 Serum albumin
The serum albumin of the children was (mean ± SD) 41.0 ± 3.8 g/l. 
Serum albumin is a indication of nutritional status in patients with chronic 
illnesses, but can also reflect disease activity in children with nephrotic
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syndrome. Levels increase with age and for children aged 3 - 1 5  years 
can range from 35 -  56 g/l.
2.2.1.2 Children with renal transplants 
(appendix 2.2)
Twenty seven children (6 females) with a renal transplant were recruited 
to the study. Patient details are in appendix 2.2, table 2.1. The (mean ± 
SD) age of the children was 12.3 ± 2.8 yrs.
Samples had been obtained previously from two children in this group 
prior to transplantation, when one had CRF and the other ESRD.
2.2.1.2.1 Primary diagnosis
Underlying diagnoses in this group were renal dysplasia -16 ( including 4 
with VUR), posterior urethral valves - 3, focal segmental 
glomerulosclerosis
(FSGS) -  5, mesangiocapillary glomerulonephritis -1 , oto-branchio-renal 
syndrome -  1, and 1 with unknown cause of CRF.
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2.2.1.2.2 Pubertal status and auxology
The pubertal status (mean ± SD) of the children was 2 ± 1. Nine children 
were established in puberty and of these four (one female) had pubertal 
delay. There were three children (one female) who were inappropriately 
prepubertal at 14 years, 16.3 years and 13.5 years (female).
Auxological parameters of all the children were as follows: ( mean ± SD) 
BMI SDS 0.9 ± 1.2, Ht SDS -1.6 ± 1.2, Ht Vel SDS 0.6 ± 3.7 and Wt SDS 
-0.2 ± 1.3. Ten children had a Ht SDS < -2 SDS.
2.2.1.2.3 Renal function and acid-base status
The GFR of the children was 43.8 ± 22.4 mls/min/1.73 m2. Three children 
had had two or more renal transplants. Mean (± SD) time since 
transplantation was 42.6 (± 26.7) months.
The mean (±SD) TCO 2 level of the children was 21.6 (± 1.9) mmol/l.
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2.2.1.2.4 Serum albumin
The mean ± SD level of serum albumin of the children was 41.0 ± 2.3 g/l. 
2.2.1.2.5 Steroid dosage
Children were on prednisolone at a dose of 0.3 ± 0.2 mg/kg/alt day.
2.2.1.3 End-stage renal disease group 
(appendix 2.3)
Ten children (5 females) were enrolled into this sub-group (demographic 
details in table 2.1). The mean (± SD) age of the children was 10.7 (± 
4.5) yrs.
2.2.1.3.1 Primary diagnosis
Diagnoses ranged from renal dysplasia -  5 (including 2 with VUR), 
posterior urethral valves -1 , congenital nephrotic syndrome -1 , focal 
segmental glomerulosclerosis - 2 and acquired disease (haemolytic 
uremic syndrome) in 1 case.
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2.2.1.3.2 Pubertal status and auxology
The pubertal status (mean ± SD) of the children was 1 ± 1. Three 
children were established in puberty, and of these two children had 
delayed development. One female at 14.3 years was prepubertal and 
thus also delayed.
The mean ± SD Ht SDS of all the children was -1.8 ± 1.2, whilst their Ht 
Vel SDS was -0.3 ± 2.4, BMI SDS was 0.1 ± 1.4 and Wt SDS was -1.0 ±
1.3.
2.2.1.3.3 Renal function and acid-base status
All patients were on dialysis treatment (2 on haemodialysis, 8 on 
peritoneal dialysis). Mean ± SD time since commencement of dialysis 
was 29.3 ± 22.1 months.
The mean ± SD TCO 2 level was 26.4 ± 2.7 mmol/l.
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2.2.1.3.4 Serum albumin
The mean (SD) albumin of the children in this group was 34.5 (± 2.6) g/l. 
This was at the lower end of the normal range (35 -  56 g/l for children 
aged 3 -  15 years). In dialysis patients this can be difficult to interpret 
as fluid overload can produce a dilutional effect.
2.2.1.4 Normal GFR group on steroid treatment 
(appendix 2.4)
Ten children (3 females), age (mean ± SD) 11.8 ± 1.7 years (median
11.4) were enrolled into the study (details as per table 2.1). This group 
with normal GFR was initially intended to be a control group to 
determine the effect of steroids without renal failure but was then used in 
the multiregression analysis as a control group with normal GFR.
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2.2.1.4.1 Primary diagnosis
Eight patients had steroid dependent nephriotic syndrome (SSNS), whilst 
two had vasculitis without renal involvement. None of these children were 
acutely unwell and those with SSNS were in remission.
2.2.1.4.2 Pubertal status and auxology
The (mean ± SD) pubertal status of the children was 2 ± 1. Three 
children were established in puberty with appropriate development. One 
female at 12.5 years was prepubertal and the only one who thus had 
pubertal delay.
The auxological (mean ± SD) measurements of all the children were as 
follows: Ht SDS was 0.2 ± 1.3, Ht Vel SDS -0.9 ± 2.2, Wt SDS 0.3 ± 1.2 
and BMI SDS was 0.4 ± 1.8.
2.2.1.4.3 Renal function and acid-base status
None of the children had diseases that affect GFR and creatinine levels 
ranged from 35 - 76 pmol/l (mean ± SD: 54.4 ± 13.8 pmol/l) and were 
normal when compared to age matched reference ranges supplied by the 
laboratory. Levels increase with age (35 -  80 pmol/l at 13 years of age)
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The acid-base status was normal for all children with a mean of 24.3 
and SD of ± 2.9 mmol/l.
2.2.1.4.4 Serum albumin
This was normal for children ( mean ± SD) at 37.4 ± 3.9 g/l.
2.2.1.4.5 Steroid dose
All children were receiving steroid treatment, and the mean (SD) dose 
was 0.4 (±0.2) mg/kg per day. Eight patients received alternate day 
steroids and 2 (vasculitis) had steroids (0.4 and 0.6 mg/kg) on a daily 
basis.
2.3 Effects of rhGH on growth and protein 
turnover (appendix 2.5)
Twelve patients (1 female) (appendix 2.5). were recruited to this study, 
and underwent preliminary studies on fractional recovery of 1-13C during
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an infusion of 1-13C sodium bicarbonate prior to proceeding on to the 
protein turnover studies (see introduction to Chapter 4 for further details). 
These patients were also included in the study of the GH-IGF-IGFBP axis 
(chapter3) where they were 8-12c, 4d, 4t, 6-9t and 2t, where c=CRF; 
t=transplant and d=ESRD (Patient 2t had CRF at the time of the 
fractional recovery study) ( appendix 2.5 ). Four patients (jfk,l.m) did not 
proceed to the protein turnover studies due to needle phobia (1), change 
of renal status with renal transplantation and cessation of rhGH (2) and 
change of renal status with development of ESRD and cessation of rhGH 
(1).
2.3.1 Patient selection
Patients were selected using the following criteria:
i) Clinical indication for rhGH treatment due to short stature. The
criteria were height standard deviation score (Ht SDS) more 
than 2SD below the mean (or below the 2nd percentile), 
despite adequate nutrition, correction of metabolic 
abnormalities, adequate dialysis and, if post transplant, 
reduction of prednisolone to a minimum.
ii) Amenable to fasting in accordance with protocol requirements.
iii) Old enough to cooperate with protocol requirements.
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iv) Not acutely unwell.
2.3.2 Age and pubertal status
The median (range) age of the children was 13.2 years (7.5 -  17.1), and 
their pubertal status ranged from 1 - 3  (median 1). Five children were 
established in puberty. Three of these (all male) were delayed with 
development below the 3rd centile appropriate for age as determined 
using appropriate age and gender pubertal centile charts. One male was 
prepubertal at 15. 2 years of age and thus also delayed in puberty.
2.3.3 Auxological and anthropometries parameters
The Ht SDS of the children ranged from -5.7 to -2.0 (median -2.7) SDS. 
Their Ht Vel SDS range was -7.1 to 8.8 (median 0.6) SDS.
The median value for the BMI for the group was 18.7 (14.9 -  28.7) kg/m2.
Anthropometries were determined only in the children who proceeded on 
to the protein turnover work. The median (range) value of triceps skinfold 
thickness of the children was 16.6 (-7.0 - 32.0) mm, and of mid-arm 
circumference was 246 (180 - 334) mm.
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2.3.4 Renal function
Six patients (a,c,f,h j,l) had CRF and 5 (b,d,e,g,m) had a renal 
transplant. One patient (k) was on peritoneal dialysis. The median 
(range) GFR of the children with CRF was 21 (12 -  34) ml/min/1.73m2, 
and of those with renal transplants was 27 (7 -  85) ml/min/1.73m2. 
Overall the median (range) was 25 (7 -  85) ml/min/1.73m2.
2.3.5 Steroid dosage
The transplanted children received prednisolone treatment on alternate 
days and the dosage range was 0.2 -  0.5 mg/kg/alt day ( median 0.2).
2.3.6 Acid- base status
The TCO 2 of the group ranged from 1 8 - 2 5  (median 22.5) mmol/l.
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Table 2.1: Mean ± SD of patient characteristics
Group
CRF
Tx
ESRD
NGFR
Age Pubertal BMI
(yrs) status SDS
11.7±3.6 2.0±1.0 0.0±1.2
12.3±2.8 2.0±1.0 0.9±1.2
10.7±4.5 1.0±1.0 0.1 ±1.4
11.8±1.7 2.0±1.0 0.4±1.8
GFR* TC02 Ht SDS
(mmol/l)
22.5±7.4 22.9±3.3 -1.4±1.5
43.8±22.4 21.6±1.9 -1.6±1.2
na 26.4±2.7 1.8±1.2
na 24.3±2.9 -0.2±1.3 
* mls/min/1.73m2
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HtVel WtSDS Creat albumin Tx Steroid Duration
SDS (umol/l) (g/i) duration (mg/kg) dialysis
(month) (month)
-0.4±3.4 -0.9±1.7 373±215 41.0±3.8 na na na
0.6±3.7 0.2±1.3 139±89 41.0±2.3 42.6±26.7 0.3±0.2 na
-0.3±2.4 -1.011.3 822±279 34.5±2.6 na na 29.3±22.1
-0.9±2.2 0.31.2 54±13 37.4±3.9 na 0.4±0.2 na
Chapter 3
Growth and the Growth-Hormone- 
Insulin-like Growth Factor axis in 
children with chronic renal failure, 
end-stage renal disease and renal
transplants
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Growth and the growth-hormone-insulin-like 
growth factor axis
3.1 Introduction
3.1.1 Endocrinology of normal growth
The many factors that influence normal growth are shown in figure 3.1. 
This chapter will focus on studying the GH-IGF-I axis in children with 
both normal and abnormal growth patterns.
3.1.1.1 Growth Hormone
GH was isolated in the 1950s. It consists of 181 amino acids and is 
coded for by a gene located on chromosome 17 within a cluster of five 
related genes in series over a 66.5 kb span. Different isoforms of human 
GH (hGH) arising from post-translation modifications can been identified 
in the circulation, with variations in molecular weight. Twenty and 22 
kDa are the main isoforms, of which the 22 kDa form is the most 
abundant (76). Both the 20 and 22 kDa forms are bioactive and can 
suppress GH secretion from the pituitary gland (77).
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GH has been regarded as important in children and adolescents, and it is 
now becoming clear that it has a role in foetal growth as GH deficiency 
leads to reduction in birth length of approximately 1 SDS (78). Its action 
appears to be most important in mid-childhood, but it is now recognised 
that it has a role in early childhood (7) and children with GH deficiency 
now receive replacement therapy in infancy. Nutrition still has a very 
strong influence on growth in this period (79).
GH is released from the pituitary gland in response to stimulation from 
GH releasing hormone (GHRH) secreted by the hypothalamus, and its 
release is inhibited by GH release inhibiting hormone (GHRIH). A diurnal 
variation in GH secretion exists, with highest levels produced at night. GH 
is released in a pulsatile manner, but although frequency and amplitude 
of the pulses are important, it appears that rate of change of serum levels 
dictates efficacy (80). Random samples, therefore, are often unreliable 
as GH levels maybe low and provide no information on rate of release of 
GH.
GH levels are also influenced by other hormones (see figure 3.1), such 
as insulin, thyroxine, cortisol and the sex steroids (during puberty); and 
other factors such as starvation, stress, sleep and exercise (7). By 
opposing the actions of insulin, GH has a “diabetogenic” effect that raises 
blood sugar levels and therefore leads to increased insulin levels (81). 
Chronic glucocorticoid therapy leads to decreased GH secretion (82).
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GH is transported in the circulation complexed to binding proteins 
(GHBP), the role of which is unclear. The structure of the GHBP is 
identical to that of the GH receptor from which it is produced by cleavage 
of the receptor from the extracellular site (83). GH actions are mediated 
via growth factors, although there is some evidence that it has direct 
influences as well on growth (84).
The GH receptor consists of a single polypeptide chain that extends 
across cell membranes. The extracellular domain is formed by the ligand- 
binding, folded amino terminal of the polypeptide chain which extends 
transmembranely to form the intracellular domain from the C-terminal 
end. GH mediates its actions by binding to two of its receptors 
(dimerization) and this initiates intracellular signalling (85) by activating 
tyrosine kinase Janus kinase 2 (JAK2) which phosphorylates itself and 
the cytoplasmic domain of the GH receptor. Inability to phosphorylate 
JAK2 leads to lack of response to GH stimulation (86).
3.1.1.2 Growth factors
Growth factors are produced by the stimulatory effects of GH on the 
liver and other tissues. Previously these were labelled " somatomedins ", 
but are now recognised as insulin-like growth factors (IGFs) as they are 
structurally homologous to proinsulin. Two forms - IGF-I and IGF-II, 7.5 
kDa molecular weight, 70 amino acids, have been identified. The type 1
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IGF receptor is a heterotetrameric glycoprotein and consists of two alpha 
sub-units containing the binding domain, and two beta sub-units 
containing the tyrosine kinase domains (87), and mediates the mitogenic 
actions of IGFs (88).
The type 2 IGF receptor binds IGF-II with high affinity, is identical to the 
cation independent mannose-6-phosphate receptor, and its role appears 
to be the degradation of IGF-II (88J.
Insulin can bind to IGF receptors with approximately 1% of the affinity of 
IGF-I. IGF-I and, particularly, IGF-II can cross react with insulin receptors 
with approximately 2% of the affinity of insulin. The affinity of IGF-II for 
the IGF type 1 receptor is about 33% of that of IGF-I (89). The insulin 
receptor is a heterotetrameric transmembrane tyrosine kinase receptor 
(88).
3.1.1.2.1 IGF-I
In addition to the liver, IGF gene expression has been detected in 
essentially all organs (84). IGF-I may have autocrine and paracrine (local 
production) as well as endocrine actions (hepatic production). IGF-I is 
believed to have a role predominately later, whilst IGF-II is more 
influential earlier in pregnancy. A correlation of cord blood IGF-I levels 
with birth size has been demonstrated (78). Levels increase with age
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postnatally. Adult levels are attained by the end of puberty, but rise 2-3 
fold during puberty.
Nutritional status influences levels of IGF-I. Fasting and malnutrition 
result in low serum levels of IGF-I, with a sub-optimal response to 
exogenous GH administration (90). Endogenous GH levels are 
increased in fasting (91). In rats, fasting leads to reduced hepatic GH 
receptors, with decreased concentrations of both GH receptor mRNA and 
IGF-I mRNA (92). Protein malnutrition may result in post receptor 
defects as neither GH receptors nor GH binding is decreased (90).
Other factors that influence free IGF-I levels are insulin, hypothyroidism 
and steroid therapy (93). The former influences an increase in levels (94, 
9 5 ), whilst reduced IGF-I levels are noted with hypothyroidism (96). 
Steroids interestingly alter IGF bioactivity by induction of IGF inhibitors 
(97).
Administration of IGF-I to rats leads to increased body weight and 
nitrogen retention, indicating protein deposition (98). Carcasses of these 
animals had reduced body fat and increased organ weights. IGF-I has 
also been shown to stimulate proliferation of differentiated chondrocytes, 
acting in synergy with GH to promote longitudinal bone growth (99). IGF-I 
gene deletion results in profound intrauterine growth retardation (IUGR) 
(78)
61
IGF-I is transported in the circulation bound to proteins, the IGF binding 
proteins (IGFBPs), which increase its half life (usually ~10 min ) (100), 
and prevent fluctuations and diurnal variations in levels. Approximately 
99% IGF-I is complexed. Free IGF is bioactive (101,102, 103). 
Imbalances between the ratio of the proteins to IGF-I can arise as in 
chronic renal failure (CRF), affecting the proportion of free IGF-I.
3.1.1.2.2 IGF-II
IGF-II levels increase gradually with age throughout childhood and 
adolescence. Levels are low in GH deficiency (104, 105) and malnutrition 
(106). IGF-II is secreted by the liver and other tissues, and rises in 
response to GH therapy in children (107). A role for IGF-II in antenatal 
growth has been established (108), but not in post-natal life. IGF-II has a 
higher affinity for the insulin receptor than IGF-I (109).
3.1.1.3 Insulin-like growth hormone binding proteins
(IGFBPs)
The IGFs circulate in the plasma bound to binding proteins-(IGFBP) (2 6 0  
amino acids in length). At least 7 IGFBPs (six "high affinity” IGFBPs (1-
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6 ) )  have been identified , found in varying quantities, in most of the 
biological fluids of the body. Other proteins which have a weaker affinity 
for the growth factors have also been identified and labelled IGFBP-rP 
(IGFBP 7). The middle region of each BP is characteristic for each 
protein (110).
Experimentally it has been shown that the binding proteins can have an 
inhibitory effect on the actions of the IGFs, presumably by reducing the 
free amount available to bind to the receptors as IGFBPs have a higher 
affinity for IGFs. It is postulated that smaller IGFBPs (IGFBP-1 and -2) 
may inhibit IGF actions at tissue level by binding to IGF in extravascular 
spaces (64). In addition some evidence indicates that the IGFBPs may 
have a direct inhibitory role in the absence of IGFs. In certain situations 
IGFBPs appear to have an enhancing influence by increasing delivery to 
the target sites, and reducing clearance of the growth factors (110).
3.1.1.3.1 IGFBP-1
IGFBP-1 gene expression occurs primarily in the liver, decidualized 
uterine endometrium, ovary granulosa cells and kidney (111J. Levels are 
regulated predominantly by insulin which inhibits transcription of IGFBP- 
1, but have also been shown to decline with age, correlate inversely with 
increases in IGF-I, and decrease during pubertal development (112). 
Thyroid hormone (113) and epidermal growth factor (114) stimulate gene
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expression, as do glucocorticoids in conditions of low or absent insulin 
levels (115). Cytokines - interleukin-1 p (IL-1p), TNF-a and interleukin-6 
(IL-6) stimulate IGFBP-1 production (116).
IGFBP-1 appears to inhibit the influence of IGF-I on somatic and brain 
growth as observed in transgenic mice that over express IGFBP-1 (1M). 
IGFBP-1 administered intravenously increases blood glucose levels and 
thus may have a role in carbohydrate metabolism (118). Low 
concentrations of IGFBP-1 enhance the actions of IGF-I by an increase 
of its half-life (119). IGFBP-1 levels are raised in intra-uterine growth 
retardation (78).
3.1.1.3.2 IGFBP-2
This binding protein is the second most abundant binding protein in the 
circulation and preferentially binds IGF-II over IGF-I. Both IGF-II and 
IGFBP-2 appear to have important roles in fetal development and growth
(120). Transgenic mice overexpressing IGF-II have raised levels of 
IGFBP-2, suggesting a role for IGF-II control in the synthesis of IGFBP-2
(121). Elevated levels are also found after fasting and in certain 
pathological conditions such as diabetes mellitus, malignancies, cirrhosis 
and CRF (122).
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IGFBP-2 appears to have a role in inhibiting the actions of IGF-II in 
animal models, leading to reduction in organ and carcass weights (123). 
In cell culture studies IGFBP-2 inhibits the autocrine IGF-II dependent 
proliferation of human colonic carcinoma cells (124).
3.1.1.3.3 IGFBP-3
This is the most abundant IGFBP in the circulation by several fold, and in 
the adult, highest tissues concentrations occur in the kidney. Its affinity 
for the IGFs exceeds that of the other IGFBPs. IGFBP-3 associates with 
an acid-labile unit (ALS -  80kDa) after binding IGF-I or -II, forming a 
150kDaternary complex that is too large to leave the circulation. Addition 
of ALS to the IGF-IGFBP-3 binary complex increases IGF half-life from 
20-90 min to 12-14 hr (100).
Differences in molecular weight, usually 41 and 38 kDa, arise due to 
variation in N-terminal glycosylation of IGFBP-3, with a 29 kDa core 
molecular mass which has a lower affinity for IGF-I (125).
GH stimulates production of IGFBP-3 from kidney, liver, spleen, heart, 
and muscle, the function of which appears to be to act as a reservoir of 
IGF-I and -II, thus preventing rapid changes in levels and potentiating 
their actions (126). IGFBP-3 may also have effects on growth that are
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independent of IGF and can be inhibitory (127). Levels increase with age 
and as nutritional status improves (110).
3.1.1.3.4 IGFBP 4-6
Only a brief mention of these proteins is necessary as these were not 
included in the study. These binding proteins are predominantly located 
within the tissues.
IGFBP-4 in adults is involved in bone formation and resorption (128), 
and in vitro inhibits the actions of IGF-I and -II (129).
IGFBP-5 is the most abundant IGFBP in bone extracts where it appears 
to be essential for IGF storage, especially IGF-II (130). Recently it has 
been identified as a component in the ternary complex formed with IGF 
and ALS in the circulation (131). Levels rise with GH treatment.
IGFBP-6 has a markedly higher affinity for IGF-II than IGF-I. It is found in 
a variety of tissues and although associated with inhibition of tumour cell 
growth in vivo and vitro (130), probably via IGF-II inhibition, its exact role 
remains unclear.
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3.1.1.4 Proteases
These are enzymes that disrupt the binding of IGF to IGFBP by 
proteolysis of the binding protein, thus lowering its affinity for IGF. They 
are specific for each IGFBP, and so far proteases for IGFBP-2, -3, -4 and 
-5 have been identified (110).
3.1.1.5 Other hormones
Hormones such as insulin and thyroxine are important in growth. 
Classically these are not part of the GH-IGF axis. Proinsulin has 
significant structural homology (~50%) with the IGFs and weak cross­
stimulation of the receptors can be observed (110). Receptor structure 
and stimulatory pathways are similar for IGF-I (IGF-IR) and insulin (IR)
(133). Mice lacking both receptors are more growth retarded than those 
lacking either receptor alone. Absence of IR leads to approximately 10% 
reduction in size at birth. In humans absence of the IR leads to 
hypoglycaemia due to overstimulation of IGF-IR by elevated insulin levels
(134). Insulin has an important role in protein turnover, fat metabolism 
and is also involved in the regulation of IGFBP-1 (135,)
Deficiency or excess of thyroxine leads to alterations in growth and 
metabolism. Thyroxine is also important in cerebral function.
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Hypothyroidism is associated with a fall in pituitary GH mRNA levels 
which are restored with treatment with thyroxine (7).
Sex steroids are important in supplementing the actions of GH, most 
noticeable during puberty. Low levels observed in delayed puberty, or 
absent puberty as in girls with Turners syndrome, result in short stature 
that responds to replacement sex steroid therapy (136).
3.1. 2 Endocrinology in CRF and renal transplantation
Abnormalities of the endocrine axis are well recognized in CRF. The 
kidneys are involved in the clearance of some hormones such as GH 
(137), levels of which are affected by loss of functional renal tissue. 
Insufficient nutritional calorie intake in CRF has endocrinological 
implications as well. Renal osteodystrophy arises secondary to low 
serum calcium, elevated phosphate and low Vitamin D metabolite levels 
(27). Parathyroid hormone (PTH) can be markedly elevated.
GH levels are either normal or increased, with preservation of amplitudes 
and frequency of pulses and a rise in basal levels in CRF (138), whilst 
the transplanted population, in whom steroids are used as an 
immunosuppressive agent, tends to have low levels of GH (139). Ferraris 
showed that the area under the curve (AUC) for GH levels in response
68
to GHRH was smaller in the transplanted population than in the CRF 
group (140). He also found that the amplitude of the spontaneous 
overnight pulses were higher in the CRF group (140).
Levels of IGF-I measured using radioimmunoassay have been found to 
be in the low - normal range (141) whilst IGF-II may be normal or 
elevated in children with CRF compared to normal controls (64, 142) 
despite elevated GH, indicating resistance to the actions of GH. 
Additionally there may be some inhibition of the action of IGFs with loss 
of the negative feedback loop which normally suppresses GH 
production. This maybe due to the elevated IGFBPs (142, 143). The 
most important of these is IGFBP-3 and raised levels are predominantly 
caused by high levels of the 29 kDa fragment, although some workers 
have found elevation of fragments of other molecular weights such as 19 
and 14 kDa (125). In healthy controls, it appears that the total molar 
value of IGF-I and -II approximates that of IGFBP-3, as it appears that 
one mole of each binds in the 150 kDa complex (144), but in CRF this 
relationship is lost. IGFBP-1 and - 2  levels are also raised (143).
Relationships observed in normal prepubertal controls, such as the 
correlation of IGF-I or IGFBP-3 with Ht SDS, appear to be absent in CRF 
(143).
A constellation of endocrine abnormalities have been reported in children
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with CRF as a result of numerous studies. This thesis reports on a study 
conducted to elucidate the effect of CRF and steroid therapy on 
endocrine function, and in particular on IGF bioactivity, in children with 
normal and abnormal growth. Studies published previously have focused 
on children with short stature (107,139,140).
The study was limited by the lack of control samples from healthy 
children with normal growth. Data from children with normal GFR but on 
low dose, steroid treatment (alternate day predominantly) was used as 
controls for statistical purposes. Historical data from normal, healthy 
children was supplied by the laboratory as a reference range for each 
assay where available . It has also been assumed that children complied 
with fasting requirements as requested.
3.2 Hypothesis
The hypothesis for the study was that levels of endocrine factors 
comprising the GH-IGF-IGFBP axis and their importance to growth are 
altered by deteriorating GFR and steroid usage and this will influence 
the Ht SDS and Ht Vel SDS of patients with CRF, ESRD and renal 
transplants.
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3.3 Aim
The aim of the research was to study clinical and endocrinological 
parameters in children with moderate and severe CRF and in those on 
steroid therapy, with or without growth retardation, to determine the 
importance of each variable to Ht SDS in all the children and to Ht Vel 
SDS in prepubertal children.
3.4 Methods
Auxological measurements and blood samples were obtained from each 
child on the same morning. Samples were collected following an 
overnight fast, with only water permitted until collection time. These were 
obtained at, or as close to, 9.00 am whenever possible. Two children 
were on overnight tube feeds which were discontinued at least 6 h prior 
to sampling time. Those on peritoneal dialysis (PD) maintained their 
normal
exchange pattern, and as the dialysate contains glucose, samples from 
children on PD cannot strictly be considered fasting as glucose 
absorption occurs. This could potentially affect some results (GH, IGFBP- 
1, insulin). Children on haemodialysis (HD) had samples collected prior 
to the dialysis session by the staff on the Dialysis Unit simultaneously 
with routine clinical samples.
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Samples for endocrine investigations were taken to the laboratory and 
centrifuged for 5 minutes at 3000 revolutions per minute. The 
supernatant was pipetted into clean tubes and frozen at -70° Centigrade 
until the time of analysis.
Families were requested to defer the medication of the subjects until 
after sample collection. Those on steroids were instructed to leave a 
minimum interval of 24 hours between dosage and sampling, or if on 
daily steroids, to take the medication as early as possible on the 
preceding day.
On their arrival at clinic, auxological measurements were undertaken. An 
upright Harpenden stadiometer (Harpenden, Crymych, UK) was used to 
measure height, whilst weight was obtained using an electronic scale 
with a digital display precision of 10 gm (SECA). Both instruments were 
calibrated prior to use, and all measurements were obtained by the same 
individual (researcher). Pubertal status was determined according to the 
Tanner and Whitehouse criteria (145). A retrospective height recorded 
wherever possible 12 months (minimum 9 months) prior to the current 
measurement was also obtained from the notes to calculate height 
velocity.
Height (Ht), and Ht Velocity (Ht Vel) were converted to standard deviation 
scores (SDS) using the following equation
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SDS = (Sp -  Sm) /  SD
whereby Sp is the subject’s measurement, Sm is the mean of the 
population , and SD is one standard deviation of the population from 
which the mean was calculated. SDSs enable ease of comparison for 
values with a Gaussian distribution that vary with age and gender.
Normal data obtained for derivation of new reference curves was used to 
calculate SDS (10).
The value of Ht Vel SDS in children of pubertal age is controversial, 
especially in renal patients in whom puberty can be delayed and the 
growth spurt abnormal (16). For this reason data from children of an age 
when healthy children were likely to have commenced puberty (females 
aged > 11 yrs, males > 12.5 yrs) were excluded when statistical analysis 
was performed to determine if any relationship was present between the 
clinical and endocrinological variables and Ht Vel SDS.
BMI was calculated from the height and weight of the children, and SDS 
were derived using age and sex matched reference data (155).
The aetiology underlying the renal disease was obtained from the notes. 
Further details of this are provided in Chapter 2.
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GFR was obtained from the notes for children with CRF and post-renal 
transplantation. Creatinine levels were also obtained from routine clinical 
monitoring. Children on dialysis have ESRD and GFR is not monitored in 
this group as it is minimal, and creatinine levels are extremely elevated. 
Group 3 children had no renal impairment, thus normal GFR 
(>80mls/min/1.73m2) and creatinine levels for their age. Therefore for 
both Groups 3 and 4, these values were not available.
Due to the nature of the study which involved blood sampling, ethical 
approval to obtain samples from healthy children was not sought, and 
hence where possible, historical normal values provided by the laboratory 
carrying out the analyses were used for comparison.
3.4.1 Sample analysis
GFR was calculated from the clearance of chromium51 EDTA as 
described previously (146).
Creatinine samples were analysed routinely in the hospital laboratory 
using an Ortho Clinical Diagnostics Vitros analyzer.
Normal values (median and whole range) were supplied by DSL to the 
laboratory for samples analysed using kits available commercially.
Normal values for IGF bioactivity were obtained from Dr Taylor's thesis
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(102) and have been published (101). Normal mean values for ALS on 
age matched children were obtained from published work (147).
Historical normal values for age matched children for IGF-I were 
available in the laboratory from a previous study from which reference 
curves for the SDS of IGF-I and IGFBP-3 were derived and these were 
used to calculate SDS (148).
All samples were batched, and analysed simultaneously by an 
experienced MLSO, J. Jones, using commercially available kits 
manufactured by Diagnostic Systems Laboratory (DSL-Texas), except for 
GH , IG F -I, IGF bioactivity , GH hybritech assay and protease.
3.4.1.1 GH radioimmunoassay
GH was measured by radioimmunoassay (RIA) by J.Jones to determine 
levels in accordance with the technique of the North Thames Regional 
Unit. Here both sheep and monoclonal mouse anti- GH antihuman 
antibodies are raised. The mouse antibody is labelled with radioiodine 
(125l). The assay provides a sensitivity of 0.2mU/l. This assay does not 
distinguish between the different molecular weights (Isoforms) of GH.
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3.4.1.2 IGF-I radioimmunoassay
IGF-I samples were analysed by RIA, using an in house technique. 
Mouse monoclonal antibodies against highly purified human IGF-I were 
raised. Label was prepared from radioactive 125l-lodine. Standard 
dilutions are carried out to provide a sensitivity of 0.15 to 6 u/ml. 
Separation of IGF-I from its binding proteins was achieved by acid- 
ethanol extraction prior to RIA. There is concern about inadequate 
removal of IGFBPs by acid-ethanol extraction (149), but results 
comparative to those obtained by
acid chromatography have been obtained using both techniques on the 
same samples (150). The assay was performed by J. Jones.
3.4.1.3 IGF bioactivity
In this technique, which has been verified previously with serum from 
acromegalic and pituitary deficient patients, and was modified by Dr 
Taylor, porcine costal cartilage discs are pre-incubated in Ham’s F-12, 
IGF free, complete culture medium for 24 hours before a 36 hour 
incubation with serum added for the uptake of 35S-sulphate and 48 hour 
incubation for 3H-thymidine. The assay was performed by Dr Taylor.
76
3.4.1.4 IGF-II
Levels were assessed using a two site radioimmunometric assay (IRMA) 
principle. Separation of the IGF-II from its binding protein is carried out 
by acid-ethanol extraction, and then it is “sandwiched” between two 
antibodies, the first of which is immobilized inside a tube wall, and the 
second is radiolabelled for detection. Four-fold over estimation of IGF-II 
by
this assay but 1.5 x by acid-chromatography due to “interference” by 
IGFBPs in uremic serum has been described (149).
3.4.1.5 IGFBP-1 a n d -3
As the assay to determine levels of both these binding proteins is similar 
in technique, only one description is provided. Using a two site 
immunoradiometric technique whereby the first antibody is bound to the 
inner wall of the tube, and the second is radiolabelled, enabling total 
levels to be assessed. The state of the IGFBP, whether free or 
complexed does not interfere with the assay, and there is no cross­
reactivity with other BP.
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3.4.1.6 IGFBP-2
Serum IGFBP-2 is measured using the same technique as that described 
for C-peptide and insulin below.
3.4.1.7 ALS
Total serum ALS (complexed and free) is measured by this 
immunoassay. Incubation of samples and controls in microtitration wells 
coated with site specific anti-ALS antibody was carried out. After washing 
the wells were treated with another anti-ALS antibody labelled with the 
enzyme horseradish peroxidase (HRP), incubated, washed and then 
incubated with tetramethylbenzidine, acidified, and enzymatic turnover of 
the substrate is carried out using dual wavelength absorbance 
measurement at 450 and 620 nm.
3.4.1.8 C-Peptide and insulin
The analysis of c-peptide and insulin is based on the same principle, 
and depends on competition between radioactive C-peptide/ Insulin 
(125l- C-peptide/ insulin), and non-radioactive C-peptide/ insulin for a 
fixed number of antibody binding sites. The amount of antigen (125l- C-
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peptide/ insulin) bound to the antibody is inversely proportional to the 
concentration of the unlabelled antigen. A double antibody system is 
used to separate free and bound antigen. The sensitivity of this 
procedure is Q.01ng/ml.
3.4.2 Statistics
As only ranges were supplied by the laboratory for normal historical 
values comparison with mean values of samples only was possible but 
not use of statistics to determine significance.
Stepwise multiregression analysis was used to determine, with the 
assistance of Professor Tim Cole, which of the variables listed below 
(see results) significantly influenced Ht SDS in all the children and Ht Vel 
SDS in the prepubertal children. As stated above, data from healthy 
children was not available for comparison, and therefore the children 
with a normal GFR were used as the constant group.
P < 0.05 was set as the significance level.
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3.5 Results (Table 3.1, table 3.2, figure 3.2)
The parameters studied for significant influence on Ht SDS were divided 
into clinical ( age, gender, aetiology of renal disease, BMI SDS, dose of 
prednisolone, duration of dialysis, duration of transplant, GFR) and 
endocrinological ( IGF-I SDS, IGF-I bioactivity, IGF-II, IGFBP-1, IGFBP-2, 
IGFBP-3 SDS, ALS, insulin, c-peptide, IGF-I moles, IGF-II moles and 
IGFBP-3 moles). Mean values ± SD for these are shown in table 3.1.
Mean IGF-I SDS were within the normal range ( -2  to 2 SDS) for all 
groups but were lower in the children with decreased renal function, 
particularly those with CRF and ESRD. These children had higher GH 
levels than those with normal GFR ( It is important to emphasise that GH 
levels were obtained from single samples which were taken in the fasting 
state at about 9.00 am). Conversely the mean values of IGFBP-3 SDS 
for all 4 groups were raised above the upper end of the normal range (> 
+2 SDS). This elevation was borderline for those with normal GFR, but 
markedly increased for the other 3 groups with highest values present in 
the ESRD group.
IGF-II mean values for all 4 groups were increased above the upper end 
of the normal range supplied by the laboratory. Highest values were
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observed for the ESRD group with slightly lower figures for the transplant 
group and were lowest in the children with normal GFR.
Both IGFBP-1 and IGFBP-2 mean values were elevated in the group with 
ESRD but not for those children with a normal GFR. IGFBP-1 levels 
were within the normal range for the CRF and transplanted patients, 
whilst IGFBP-2 levels were increased for both groups, but not to the 
extent observed in the ESRD group.
Using multiple regression analysis, variables were independently 
analysed to determine their relationship with Ht SDS in the three groups 
- CRF, ESRD and transplant. The significant parameters were then 
entered into the equation together to obtain the best fit. This is assessed 
by adjusted R squared (R2) which is a measure of the percentage 
variability in Ht SDS and Ht Vel SDS between individuals explained by 
the significant parameters. Age, treatment modality (CRF/dialysis/ post 
renal transplant), duration of dialysis, IGF- II, and ALS all had a 
significant impact on Ht SDS. These parameters accounted for 38.4% ( 
adjusted R2) of the variation in Ht SDS (table 3.2). The former three 
variables had a negative relationship with growth, whilst the latter two 
were positive in their influence. None of the other factors influenced Ht 
SDS significantly.
IGF-II had the strongest effect on growth (P < 0.0001), and ALS was also
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significant (P < 0.02). ALS and IGF-II together accounted for 30.4% of 
the variation in Ht SDS. Figure 3.2 shows a scatter plot of the 
relationship between the residual IGF-II and residual Ht SDS values 
obtained from the multiregression analysis.
Both dialysis treatment and IGF-I SDS lost their significance when other 
variables were introduced into the step wise regression. IGF-I SDS was 
significant (P < 0.01) when analysed independently, but became 
insignificant in the presence of IGF-II, and so was excluded from the 
final model. Requirement of dialysis treatment had a significant adverse 
effect on growth when analysed on its own, but this disappeared when 
duration of dialysis treatment was added to the equation. The latter 
variable had a negative influence on Ht SDS, consistent with decreasing 
Ht SDS due to prolonged dialysis treatment.
Aetiology of renal disease, duration of transplant, steroid dose, gender, 
BMI SDS, GFR, IGF bioactivity, IGFBP-1, IGFBP-2, IGFBP-3 SDS, IGF-I 
moles, IGF-II moles , IGFBP-3 moles, c-peptide and insulin levels had no 
significant influence on Ht SDS.
Apart from a positive benefit from transplantation, where the R2 value 
was 26% (P=0.0004), none of the parameters had a significant influence 
on Ht Vel SDS.
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3.6 Discussion
Growth retardation is a major complication of both chronic illnesses and 
their treatments (151), and about 30% of the CRF and transplanted 
patients in the present study had short stature (Ht SDS = -2 SDS). Many 
factors influence growth, generally by causing an imbalance of the 
hormones involved in growth, but sometimes by a direct mechanism 
(152). By studying parameters shown to be particularly significant to 
growth in other studies, using multiregression analysis an attempt was 
made to explain the observed variation in Ht SDS in this study between 
individuals.
Of all the clinical parameters studied for the purpose of this thesis, 
treatment modality, duration of dialysis treatment and age were the only 
ones that had a significant effect on Ht SDS and this was negative in all 
three cases. Most unexpectedly, of the endocrine parameters, IGF-II had 
the greatest positive influence on Ht SDS and by comparison the 
influence of IGF-I SDS became insignificant. Surprisingly, IGF bioactivity 
and the IGFBPs had no effect on growth. Only one factor 
(transplantation) had a relationship with Ht Vel SDS that was significant.
Although BMI is conventionally used to determine “ fatness (154), a value 
under the 4th percentile is reflective of undernutrition (155) whilst a
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normal BMI in chronically ill patients does not exclude disproportionate 
fat mass to fat free mass ratio compared with healthy controls (156). In 
this study, BMI was used to exclude malnutrition as a significant problem 
in the patients. Only three children (1 CRF, 1 dialysis and 1 normal 
GFR) had a BMI SDS below -2 SDS and of these two (1  CRF, 1 
dialysis) had short stature (see appendix 2.1- 2.4). Two of the dialysis 
patients received nasogastric tube feeds. BMI SDS did not have any 
significant effect on the growth of the children. Normal growth requires 
the provision of an adequate quantity of nutrients, including vitamins, 
minerals, protein and calories so that tissue synthesis prevails over 
degradation. Malnutrition can occur in CRF, and especially in ESRD 
(153, 36), but with regular assessments by an experienced renal dietician 
and using nasogastric tube feeds if necessary, severe malnutrition can 
be prevented. Despite these measures growth retardation can still prevail 
in some children (27).
Growth suppression within the first two years of a child’s life with 
normalisation of the growth rate subsequently will result in short stature 
due to inadequate catch-up growth to compensate for the loss in height 
at a time of rapid growth (159). This has been noted most commonly in 
children with congenital renal disease (eg renal dysplasiawith or without 
vesicoureteric reflux or obstruction ). Such infants may be small even at 
birth with a weight/height 1 SDS below the mean (159). In the present 
study, aetiology of renal disease had no significant effect on Ht SDS.
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This can probably be attributed to the careful attention paid to the 
nutritional status of these children in infancy, thus minimising height loss 
in this period as demonstrated by other studies from this centre (27) and 
other centres (28, 30).
Increasing age had a significant negative influence on Ht SDS, indicating 
that children with renal disease may have growth stunting which worsens 
with time compared to their age and gender matched healthy 
contemporaries. This can be explained by the progressive deterioration 
of GFR with time, which can lead to worsening of endocrine (143) and 
nutritional status (51) contributing to a slowing in the rate of growth which 
eventually manifests as short stature. Furthermore, patients with CRF 
and post transplant can have abnormalities of pubertal development and 
this can be associated with an inadequate growth spurt, resulting in 
further decrease of Ht SDS with age (16). In the study population here 
however, puberty had no observed impact on Ht SDS. Twenty one 
percent of all the children in the study had pubertal delay, evident as 
either inappropriately prepubertal, or commencement of pubertal 
development but below the 3rd centile for chronological age. The majority 
of the children were appropriately prepubertal or in early puberty 
(pubertal stage < 3) before the pubertal growth spurt is observed in 
healthy children. In these patients abnormalities of the growth spurt 
would not be present to contribute to the observed negative relationship 
between age and Ht SDS.
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The renal modality (CRF/ transplant/ ESRD) of the patients influenced 
their Ht SDS ( table 3.2). The presence of ESRD was significantly more 
detrimental to the growth of children than either CRF or renal 
transplantation. However this relationship altered and was no longer 
significant when duration of dialysis of dialysis was taken into 
consideration. Duration of dialysis had a negative influence on Ht SDS. 
ESRD is associated with poor growth (150) but some initial improvement 
maybe noticed after commencing dialysis. However with prolonged 
dialysis, there is an increased level of morbidity and mortality (36,37), 
and in children growth is affected adversely (56). Children requiring 
dialysis treatment respond less well to rhGH (160, 162). In the present 
patient group, increased duration of dialysis had a significant negative 
effect on Ht SDS. Of the dialysis patients (appendix 2.3), 5 children had 
normal height, 4 of whom had an adequate rate of growth. These 
children had developed CRF later in childhood and had been on dialysis 
for a shorter period (not statistically proven) than those with Ht SDS <-2 
SDS. There were insufficient patients to compare the influence of 
haemodialysis to that of peritoneal dialysis.
Renal transplantation, of all the parameters measured, had the most 
negative relationship with Ht SDS with the lowest t - ratio in the best fit 
equation. This group of children also had the lowest mean Ht SDS. 
However, interestingly, transplantation was the only parameter that had
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any significant (positive) effect on Ht Vel SDS (Data of children who were 
of an age when the growth spurt may be observed, as explained in the 
methods section above, were omitted from the equation to reduce the 
confounding influence of puberty). Multiple factors can contribute to 
growth retardation pre and post-transplantation, such as the original 
disease, dialysis, episodes of graft rejection with deteriorating graft 
function, steroid therapy and retransplantation (3 patients in the present 
study). (29,32,33). However, in this study receiving a transplant 
improved the children’s rate of growth. This finding has been observed 
by other workers as well (29) and is attributed to the improved renal 
function.
In the present study, dose of steroids had no effect on Ht SDS, as this 
variable just missed being significant (P=0.06). This maybe due to the 
majority of children receiving low dose, alternate day steroids. Despite 
this, however the relationship of transplantation with Ht SDS showed a 
deterioration when steroid therapy was added to the equation, 
demonstrating an adverse influence of treatment and not dose in the 
present study. Thus it appears that whilst the children with a transplant 
had the lowest Ht SDS, growth rate improved with renal function after 
transplantation. Although improvements in height velocity can be 
observed, these may be insufficient to attain catch-up growth. It is open 
to speculation as to whether the unfavourable effect of steroids 
manifested as some suppression of the height velocity which otherwise
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would have been greater, or a slowing in growth rate with prolonged use 
of steroids. Other studies have also demonstrated a detrimental effect of 
steroids on growth (24, 156). Steroids can have a direct effect on the 
growth plate but also modulate the bioactivity of factors involved in 
growth such as IGF-I (97, 152). Glucocorticoids reduce GH secretion 
(97), increase protein catabolism (157) and act on the chondrocytes to 
inhibit mitosis (152). Treatment also lowers IGF bioactivity (97) and has 
an effect on paracrine activity of IGF-I (152) and observations from the 
present study showed that mean values of patients’ samples were lower 
than historical values from normal children.
In this study, although dialysis did have an adverse effect on growth, 
GFR had no direct effect on Ht SDS. The GFR of the CRF patients was 
lower than that of the transplanted group, but those from the latter group 
had a diverse range, confirmed by the large standard deviation. The 
mechanism by which a progressively deteriorating GFR influences 
growth adversely as shown in other studies involves decreased efficacy 
of hormones such as GH by a combination of insensitivity at receptor 
level (138) and accumulation of factors that are inhibitory to its mediators 
(142). Other factors such as nutritional state also become important. In 
uraemia, resistance to the actions of GH has been demonstrated, with 
reductions in tissue expression of IGF-I mRNA (162) and IGF-I secretion 
demonstrated using a mathematical model in the presence of low IGF-I 
levels(144). This may be due to down regulation of GH receptors in the
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presence of elevated GH levels as demonstrated by reduced GH 
receptor mRNA expression in rat hepatic tissue (163) and decreased GH 
binding protein which is homologous to the extracellular domain of the 
GH receptor (83).
IGF-I is recognised as the most important growth factor postnatally in the 
normal population (108). However in this study in children with renal 
impairment, the significance of IGF-I SDS disappeared in the presence of 
IGF-II in the multiregression analysis. The probable explanation for this 
surprising finding is IGF-I levels that would be considered comparatively 
low in a population in whom other endocrine factors (GH, IGF-II and 
IGFBP levels) are elevated (mean IGF-I SDS <1. 0). Considerable 
variation in individual values of IGF-I within groups, as demonstrated by 
the magnitude of the standard deviation of the mean, can be observed.
As discussed above, steroid treatment and uraemia have a negative 
effect on GH levels and efficacy and lead to lower IGF-I levels. Low -  
normal IGF-I values have been described in other studies (144, 150).
Free IGF is bioactive (102, 165) but no relationship was observed in the 
current study between Ht SDS and IGF bioactivity. Other studies have 
also been unable to find such a relationship. There was noticeable 
variation in bioactivity between individuals within the 3 different groups. 
Free IGF levels are dependent on IGF and IGFBP levels. A direct 
correlation between IGF bioactivity and GFR has been demonstrated and
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this is retained even when the GFR drops to 30 mls/min/1.73m2 (166). 
The assay used to determine bioactivity is an in vitro process performed 
using cartilage discs and is a very simplistic model for the complex 
process of growth in vivo and may also account for the lack of a 
relationship between growth and bioactivity.
IGF-II, which has a recognised role in early antenatal growth (108) 
interestingly had the strongest positive relationship with Ht SDS of all the 
parameters studied. The exact significance of IGF-II in postnatal growth 
remains to be clarified but some evidence suggests that it has quite a 
prominent role. It has been found to be involved in the proliferation of 
human colonic carcinoma cells and this action can be blocked by IGFBP- 
2 (124). Transgenic mice over expressing IGFBP-2 have -  13% 
reduction in carcass weight (122). Furthermore levels of IGF-II rise in 
response to recombinant GH (rhGH) therapy (139) and are low in GH 
deficient children (105). In the work carried out for this thesis, levels of 
IGF-II in the children were elevated above the normal range and were 
highest levels in the dialysis patients. Findings from other studies have 
also demonstrated that levels are raised in CRF (64, 144) due to 
accumulation secondary to the decreased clearance of IGFBPs 
(144,150). IGF-II had a very significant positive effect on Ht SDS in the 
population studied here, and part of this maybe due to its ability to 
stimulate IGF-I receptors particularly if free IGF-I levels are low. The 
actions of the growth factors are complicated by their interactions with
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each other and the IGFBPs. In transgenic mice, high levels of IGF-II 
resulted in low levels of IGF-I, most probably due to displacement with 
competition for limited IGFBPs (121).
ALS appears to have a role in growth promotion by increasing the half- 
life of IGFs further by stabilising the binary complex formed between IGF 
and IGFBP-3. This may explain the observed effect of ALS on the Ht 
SDS of the children in the present study. Levels in all patients were 
within published age matched ranges produced using the same assay 
(147) but mean values were lowest in the ESRD group who would have 
high resistance to the actions of GH due to severe uraemia. The CRF 
group who had moderate uraemia had higher mean levels than the 
transplant group who had both uraemia and received steroid treatment.
It is interesting to speculate that this may be a sensitive reflection of the 
efficacy of GH in conditions where there is resistance to its actions, 
particularly as ALS levels do not accumulate in CRF. In knockout models 
of mice, ALS deficiency is associated with slower postnatal growth (~10%  
by 21 days of age) and decreased levels of IGF-I (67%) and IGFBP-3 as 
the mice age (172). Powell studied the effects of rhGH in children with 
CRF, and noted relationships between improvements in Ht SDS and 
increases in ALS levels (64).
None of the binding proteins had any significant relationship with Ht 
SDS. Powell noted an inverse correlation between IGFBP-2 and Ht SDS
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in his study (107). However his study was performed only in children with 
CRF, and did not include ESRD or those with a renal transplant. His 
patients had IGFBP-2 levels that were marginally elevated (1.2 ±1 .2  
SDS) whilst in the present study mean levels were 2-3x higher than the 
upper end of the normal range in the CRF and ESRD patients. It thus 
maybe that excessive increases in levels of the IGFBPs distorts 
relationships, particularly when severe reductions in GFR are observed 
as in ESRD. Whilst no studies appear to have been published studying 
the effects of steroids on IGFBP-2, synthesis of IGFBP-1 can be 
stimulated by cortisol. Levels of IGFBP-1 were within the normal range 
for both the CRF and transplanted children but elevated for the ESRD 
group. Evidence of IGFBPs’ inhibition of IGF bioactivity was provided 
by Blum when serum from patients with ESRD was passed through an 
IGF-II affinity column, thereby removing excess IGFBP, leading to an 
increase in bioactivity (165). In CRF, IGFBPs are elevated (142), due in 
part to decreased renal clearance as urine from normal individuals 
contains low molecular weight BPs (< 60 kDa) (165), but there is also 
evidence of increased expression of IGFBP-1 and -2 mRNA in CRF 
(162). Studies with transgenic rabbits indicate that IGFBP-2 also inhibits 
the actions of IGF-I (169).
IGFBP-3 can have both growth promoting (126) and inhibiting effects 
(127). As the most important binding protein, it needs to considered 
separately. IGFBP-3 SDS was elevated in all 3 groups. IGFBP-3 levels
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were determined here using IRMA that does not distinguish between the 
intact molecule or the smaller fragments accumulating in CRF. If levels 
of the intact molecule had been determined, and used in the 
multiregression analysis, a relationship with Ht SDS may have been 
present. The molar sum of IGF-I and - I I  exceeded that of IGFBP-3 in 
the current study, contrary to findings in healthy individuals (144). The 
molar ratio may also reflect the increased relevance of other IGFBPs 
(IGFBP-1 ,-2,-4) than IGFBP-3 as IGF binders in CRF (167).
Insulin is an important anabolic hormone and highly relevant to growth 
and therefore needs to be discussed here. Knockout mice models 
lacking the insulin receptor (IR) show growth retardation that is mild 
(134), unlike humans where it is significant (173). In CRF, abnormalities 
of carbohydrate metabolism have been noted (174), and use of steroids 
following transplantation leads to elevated insulin levels due to resistance 
to its actions (175,) and this may explain the observed lack of effect on Ht 
SDS. Post receptor abnormalities, decreased insulin receptors and 
increased hepatic gluconeogensis also contribute to the insulin 
resistance observed in CRF (174). No relationship of c-peptide with Ht 
SDS or Ht Vel SDS was present. C-peptide has a longer half life than 
insulin in normal individuals and therefore provides information about 
insulin activity. Levels of both c-peptide and insulin in the children 
studied here were comparable to the normal ranges supplied.
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This study could have, potentially, been improved by addressing 
shortfalls that became apparent retrospectively. The major limiting factor 
of this study is the absence of results from healthy children to be used as 
controls. To compensate for this, the group with norma! GFR served as 
the constant in the multiregression analysis. Conversion of IGF-II, 
IGFBP-1 and -2 to SDS would have enabled comparison with historical 
studies performed in similar children to determine if levels are raised to 
the same magnitude in similar populations studied by different workers. 
Categorisation of GFR into normal, mild, moderate, and severe may have 
shown a relationship with growth.
In conclusion it is apparent that growth is a complex process involving 
the intricate balance of multiple factors and the presence of renal 
impairment adds to the conundrum. The aetiology underlying the CRF 
had no relationship with Ht SDS in the present study. However the renal 
modality of the children had an impact on their Ht SDS and this was 
initially most marked in the case of the dialysis patients. Interestingly 
however, after adjusting for duration of dialysis, transplantation had the 
most negative relationship with Ht SDS which deteriorated further after 
steroid treatment was entered into the best fit equation. Age also 
showed an inverse relationship with Ht SDS perhaps as a manifestation 
of progressive deterioration of GFR adversely affecting growth due to 
worsening of endocrine abnormalities. Of the endocrine parameters, IGF- 
II had the strongest positive influence on Ht SDS and this may be partly
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due to a direct effect, but also its ability to stimulate IGF-I receptors. 
Mean levels were elevated in the three groups of patients and highest in 
the ESRD group. In contrast, IGF-I (SDS) mean levels would be 
considered lowish for this population although normal for healthy 
children. ALS also was significant to growth. IGF-II and ALS levels, 
duration of dialysis, age and renal modality explained 38.4% of the 
variability in Ht SDS, with approximately 61% unaccounted for, and 
therefore there are other factors not considered here that contribute to 
the growth process.
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Table 3.1 Mean ± SD of clinical and endocrinological variables
Parameters normal levels
(mean; range)
CRF
(mean±SD)
Tx
(mean±SD)
ESRD
(mean±SD)
NGFR
(mean±SD)
Age (years) na 11.7 ±3.6 12.3 ±2.8 10.7 ±4.5 11.4 ±1.7
Puberty na 2 ±1 2 ±1 1 ±1 2 ±1
BMI SDS na 0.0 ±1.2 0.9 ±1.2 0.1 ±1.4 0.4 ±1.8
GFR (mls/min/1.73m2) na 22.5 ±7.4 43.8 ±22.4 na na
Ht SDS na -1.4 ± 1.5 -1.6 ±1.2 -1.8 ±1.2 -0.2 ±1.3
Ht Vel SDS na -0.4 ± 3.4 0.6 ±3.7 -0.3 ± 2.4 -0.9 ±2.2
Transplant duration (months) na na 42.6 ±26.7 na na
Dialysis duration (months) na na na 29.3 ±22.1 na
steroid dose(mg/kg) na na 0.3 ±0.2 na 0.4 ±0.2
GH RIA (mU/l) 2.2 (0.5 - 5.4) 13.7 ±17.8 11.8 ±16.2 8.8 ±4.7 6.1 ± 5.4
IGF-I SDS -2 to 2 0.55±1.48 0.91±1.12 0.79±0.77 1.48±1.26
IGFBP-3 SDS -2 to 2 3.19±1.09 3.39±0.70 3.99±0.78 2.53±0.62
IGF Bioactivity (u/ml) 0.9 (0.5-1.2) 0.41 ±0.40 0.73±0.56 0.35±0.21 0.80±0.43
IGF-II (ng/ml) 869 (752 - 972) 1189±361 1358±281 1555±243 1036±245
IGFBP-1 (ng/ml) 59 (12-27) 96.2±40.7 84.1 ±36.7 127.1 ±36.5 33.5±16.9
IGFBP-2 (ng/ml) 410(100-675) 1169±447 863±452 2085±881 409±121
CPEP (pmol/l) 497 (265 - 1324) 323.6±357.1 625.7±1441.0 565.1 ±762.5 414.9±551.7
Insulin (mU/l) 15(3-35) 14.1±5.6 12.3±7.4 14.5±10.7 17.5±14.8
ALS (mcg/ml) na 38.9±23.6 32.3±6.2 28.4±4.7 47.7±17.01
IGF-I mol na 114±72 112±59 54±16 59±24
IGF-II mol na 154±47 177±37 202±32 135±32
IGFBP-3 mol na 168±44 178±29 204±32 143±27
Table 3.2 Best fit multi-regression model for Ht SDS
R2 = 38 .4%  (Dependent variable Ht SD S )
Variable Coefficient s.e t-ratio probability
constant -0.50 0.84 -0.63 0.50
transplant -1.91 0.49 -3.92 <0.01
CRF -2.19 0.62 -3.52 <0.01
dialysis -1.57 0.92 -1.68 0.10
female -0.03 0.29 -0.10 0.90
age -0.12 0.04 -2.83 0.01
IGF-II <0.01 <0.01 3.63 <0.01
ALS 0.02 0.01 2.47 0.02
Steroid dose -2.08 1.09 -1.90 0.06
dialysis duration -0.04 0.02 -2.76 0.01
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Figure 3.1 Factors influencing levels of Growth Hormone
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Figure 3.2: Scatterplot of residual of IGF-II and 
residual of Ht SDS in multiregression analysis
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Chapter 4
Effects of recombinant human 
Growth Hormone on protein 
turnover, growth and endocrine 
factors in children with CRF and 
renal transplants
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Protein turnover and growth with rhGH
4.1 Introduction
4.1.1 Protein kinetics
Children with chronic renal failure (CRF) easily become malnourished if 
inadequate attention is paid to their caloric intake (40). Even in the 
absence of visible malnutrition their lean body mass tends to be reduced 
(176). As the renal failure worsens dietary assessment and 
supplementation may be required. However, protein restriction (which 
may be necessary in uraemia) decreases lean body mass further (177), 
whilst excessive dietary protein intake results in decreased flux and 
synthesis (178).
Body protein is dynamic and is continuously being degraded to, and 
synthesised from, amino acids with the balance of the two processes 
determining whether there is net protein deposition (179). Protein 
kinetics, with or without recombinant human Growth Hormone (rhGH), 
have been studied in adult patients with CRF and in healthy volunteers 
(180, 181, 182). In CRF findings have been reported of an increase in 
the rate of catabolism and oxidation, particularly in the presence of 
acidosis (183); an increase in catabolism and synthesis with no change 
in net balance (180); or decreased rate of protein catabolism and
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synthesis with a lower synthesis to flux ratio (178) compared to controls. 
Other studies have examined the effects of restricted nutrition (normal 
control rats pair-fed to match caloric intake of uremic animals) (184) and 
acidosis in the absence of CRF. Studies have also been conducted to 
observe the influence of glucocorticoids on protein turnover in animals 
(185) or the effects of differing quantities of dietary protein intake on 
protein turnover (178). Fewer studies have been conducted in children 
and these have shown that healthy children have a higher protein 
turnover than adults that decreases with age (186, 187,188, 189). In 
severe CRF in adults protein turnover is reduced, with some 
improvement noted once dialysis commences without normal levels 
being attained (183, 187).
RhGH increases fat free mass (FFM), with a reduction in adipose tissue 
in growth hormone (GH) deficient adults (190). In adults with CRF (191) 
findings are similar to observations in healthy adults (157) and consist of 
a reduction in oxidation of amino acids with increased synthesis and 
unaltered proteolysis with the use of rhGH. However Garibotto’s study 
measured kinetics in forearm muscle only (180,191).
Factors that influence protein synthesis and oxidation are uraemia (184, 
192), acidosis (185), quantity of daily dietary protein intake (178, 187) 
and corticosteroid therapy (157). These may have a direct influence on 
amino acid incorporation into protein, but the effect may also be
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mediated via hormones, the response to which may be altered (180, 
191). Metabolism of branched chain amino acids and their keto acids is 
abnormal in CRF compared with controls (194).
4.1.2 Endocrine factors involved in protein turnover 
and growth (as discussed in chapter 3)
4.1.3 Use of rhGH in CRF
Trials of GH therapy in children with CRF were not carried out until 1983 
when Mehls and Ritz (195) demonstrated that supraphysiological doses 
of GH increased growth velocity in 5/6 nephrectomized rats, particularly if 
they were fed ad libitum (196). Pilot studies over one year confirmed that 
recombinant GH (rhGH) led to increased height velocity in children with 
CRF (197), or post renal transplantation (198). These findings were 
confirmed by a randomised, placebo-controlled crossover study (199) 
and a two year multicentre trial (200).
Fine, in a prospective study, showed that improved growth due to rhGH 
was sustained over five years compared with the pre-treatment period, 
although the growth velocity decreased in each subsequent year of 
treatment (201). Once children had attained their target height, rhGH
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therapy was interrupted. Some children maintained their growth velocity, 
whilst in others it dropped to pre-treatment levels, necessitating 
recommencement of rhGH.
4.1.4 The use of stable isotopes
Stable isotopes, by incorporation into organic compounds such as amino 
acids, have been used in metabolic and nutritional studies since the 
1950s. They are naturally occurring variants of isotopes such as carbon 
(12C, stable isotope 13C) and hydrogen (H, stable isotope 2H) that are 
present in the environment in very small concentrations. They can 
therefore be used as “labels” and traced in metabolic reactions. No 
radioactivity is present, thus they overcome the potential dangers posed 
by radioactive tracers used previously. Use of stable isotopes has also 
been enhanced by the development of better mass spectrometers that 
can analyse very small samples (202).
Whole body protein is constantly being synthesised and degraded, and 
the process accounts for 15-20% of the resting metabolic rate (179). 
Many amino acids can be synthesised in man, but some termed 
“essential” cannot, and therefore need to be ingested in the diet. One 
amino acid pool is located intracellularly, and amino acid entry into the 
pool occurs either from protein catabolism, active transport from plasma, 
synthesis de novo or conversion from ketoacids (figure 4.1). Amino acid
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removal from the pool occurs by either synthesis of protein, oxidation or 
release into the circulation. The first step in oxidation is loss of a-nitrogen 
by transamination (except lysine) or oxidative deamination to the 
ketoacid of the amino acid, and in some cases this is a freely reversible 
reaction. The tissue in which metabolism of different amino acids occurs 
varies. Leucine can be metabolised in skeletal muscle and liver, whilst 
phenylalanine can only be metabolised in hepatic tissue and glutamine is 
metabolised by gut and kidney (202).
Validation of protein turnover studies has been performed by using stable 
isotope infusions, and comparing protein kinetic results with muscle 
biopsies (203), or using animals which have then been sacrificed and 
their muscle homogenized (204). Using two different amino acids 
simultaneously with separate labels also provides further information 
about the accuracy of the technique (205).
Studies of protein kinetics using continuous infusions are based on the 
assumption that there is a single pool involving the labelled amino acid 
and that the concentration of this amino acid in the pool does not change 
in the steady state and thus is representative of its turnover. Therefore 
the rate of entry of the amino acid into the pool must equal its rate of 
removal from the pool. Entry into the pool (rate of appearance) occurs 
from either diet, or protein catabolism, whilst removal (rate of 
disappearance) is by either irreversible oxidation or protein synthesis
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(206). The rate of appearance of the amino acid can be restricted to that 
originating from catabolism only by conducting studies with the patient 
fasting or postabsorptive, eliminating the ingested component. By using 
infusions of labelled amino acids, the proportion of the labelled amino 
acid to unlabelled amino acid remains constant, as the metabolic 
processes do not distinguish between the two (202). The enrichment, or 
percentage dilution of the labelled to unlabelled amino acid, is obtained 
from samples in the steady state and using this calculations of turnover 
can be made. Using the enrichment of CO 2 in breath samples, the rate of 
oxidation of the amino acid can be calculated and hence rate of non- 
oxidative disposal (synthesis) of the amino acid can be determined.
4.1.5 Leucine kinetics (Figure 4.2)
Leucine is frequently used as the amino acid to carry the stable isotope 
13C as it an essential amino acid. Its removal from plasma into the 
intracellular compartment is by an energy dependent process. From here 
removal is either by incorporation into protein synthesis, or oxidation 
which will lead to carbon dioxide (CO2) production. The advantages of 
using leucine are that it reaches steady state, whereby the rate of entry 
of leucine into the plasma pool is equal to its rate of removal from the 
pool, within 1.5 hours of commencing an infusion, thereby shortening the 
duration of studies. 1-13C-Leucine is easy to infuse intravenously, and 
can provide information on whole body protein kinetics. It is metabolised
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peripherally in skeletal muscle, the body’s principal protein reservoir, and 
leucine appears to have a regulatory role on muscle protein synthesis 
and degradation (207, 208). Intracellularly leucine equilibrates rapidly 
with its metabolite ketoisocaproic acid (KIC), and is one of three amino 
acids that will do this. The short study period minimises the likelihood of 
recycling of the isotope, which can complicate studies, and urinary 
losses. Infusing the label avoids the complication of faecal losses. The 
disadvantage of using leucine is that it is oxidised to release CO2 , 
thereby necessitating collection of breath samples and calculation of CO2 
volume production using indirect calorimetry.
Oxidation of amino acids like leucine results in CO2 production, but not all 
the CO2 produced is released as breath due to CO2 fixation and entry into 
other pools with a slower turnover rate, such as bone (209). In order to 
determine the percentage of labelled leucine oxidised, the percentage of 
labelled C 0 2 recovered in breath must be determined. Therefore studies 
using labelled sodium bicarbonate (H 13C 0 3 _) have been performed (210). 
H 13C0 3 _ is infused at a constant rate until steady state is reached. Breath 
samples are then obtained to determine the enrichment of CO 2 , and by 
measuring the volume of CO2 produced per minute, the percentage of 
infused H13C0 3 ' recovered can be calculated. In short term studies 
(<12h), in healthy adults about 81% of the label is recovered (210). This 
figure is then used in leucine oxidation calculations as a corrective factor. 
Studies of fractional recovery or percentage of 13C recovered in children
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are limited, and figures ranging from 63-94 % have been obtained 
depending on method of administration of label (209). Recovery in 
children with renal impairment has not been determined, and in these 
studies the conventionally accepted figure of 0.81 has been used (211), 
although studies involving other paediatric patients have used their own 
calculated corrective factor (212).
It is now considered more appropriate to use the enrichment of KIC in 
calculations of protein turnover (213). Leucine rapidly equilibrates with 
KIC intracellularly, as the transamination step is reversible. KIC thus 
provides more accurate values for the intracellular enrichment of leucine 
at the site of protein synthesis, degradation and leucine oxidation. 
Intracellular KIC concentrations in turn equilibrate rapidly with the plasma 
pool of KIC.
4.1.6 Effect of feeding on protein kinetics
Most studies are conducted in the postabsorptive state, as intake does 
not have to be accounted for. This simplifies the model for protein 
turnover and calculations. Endogenous substrates are used as fuel 
sources to provide energy when feeding does not take place and the 
respiratory quotient provides an indication of the substrate (fat, 
carbohydrate, protein) predominantly being metabolised (214).
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Feeding increases rates of whole body and skeletal muscle protein 
turnover, with all parameters (except whole body protein breakdown) 
significantly higher in fed individuals compared to fasted. Although 
leucine oxidation is increased, the net protein balance is higher in fed 
individuals (203).
4.1.7 Limitations of stable isotope studies
In stable isotope work, certain assumptions are made:
i) The stable isotope is not differentiated from the usual isotope by 
the metabolic processes in the body.
ii) Perfect equilibration occurs of intra and extracellular KIC, and 
between leucine and KIC intracellularly.
iii) Assumptions regarding intracellular events involving leucine and 
KIC are accurate, and leucine is not metabolised directly without 
being equilibrated.
iv) Samples obtained accurately reflect intracellular protein kinetics 
and have not altered between point of release into the circulation 
and sampling.
v) No alteration of isotope enrichment in the infusion syringe occurs 
or sampling tubes occurs.
vi) Minute CO2 production rate measured during indirect calorimetry 
is representative of that throughout the study.
vii) Recycling of label during the study does not occur.
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viii) Protein turnover rates are constant throughout the day with no 
circadian rhythm in the postaborptive state.
ix) In disease, kinetics of the amino acid still follow those observed in 
health.
x) The fuel being metabolised during the study does not alter to any 
extent, as fat has a lower natural enrichment than carbohydrate.
4.1.8 Protein turnover in children with CRF
Studies of protein turnover in children with CRF are limited, with only two 
previous studies identified (187, 211). Both studies included patients with 
CRF/ ESRD but not those with a renal transplant. In the former study the 
amino acid used to carry the stable isotope was lysine, which is 
metabolised in the liver and not skeletal muscle. The ages of the patients 
ranged from 4.1 to 18.8 years. The samples were obtained when a 
steady state had been reached, postabsorptively. Flux was the only 
parameter assessed, and was compared with historical normal values 
obtained from literature, and found to be substantially lower, with no 
significant improvement following a dialysis session. No information on 
the rate of protein synthesis or oxidation was provided.
The second study compared protein kinetics in children with CRF, who 
were and were not acidotic, and noted that acidosis leads to increased 
catabolism and amino acid oxidation (211).
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In this thesis studies of protein turnover in children with renal transplants 
with comparison to findings in those with CRF has been undertaken 
before and after use of rhGH, and do not appear to have been conducted 
previously. In adults with CRF, improvements in protein synthesis have 
been noted with use of rhGH (191), but there is no information on the 
effects of rhGH on protein turnover in children with CRF and renal 
transplants.
Performing studies in children is dependent on the age and ability of the 
child to understand and comply with requirements. In the protein kinetic 
studies it had to be assumed that all children fasted as requested. The 
children had to remain on bed rest for the duration of each study but 
most did not lie still and some times had difficulty staying awake. The 
protocol entailed the use of rhGH, and patient compliance with daily 
injections had to be assumed, although this can be verified partially by 
the results obtained. Physiological differences in follow up studies could 
not be taken into account, nor the changes in stages of growth which 
maybe very relevant when some patients are of pubertal age. Equipment 
was calibrated prior to use, but does not fully exclude artefacts, 
especially during indirect calorimetry.
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4.2 Hypothesis
Use of rhGH in children with CRF and renal transplants will improve 
growth, lean body mass, reduce adipose tissue and increase protein 
turnover that maybe reduced compared to healthy individuals.
4.3 Aim
The aim of this study was to determine protein turnover at baseline in 
children with CRF and those who had had a renal transplant, and study 
how it altered, along with growth and the GH-IGF axis, with use of rhGH 
therapy.
4.4 Method
Protein turnover was measured using isotopicaly labelled leucine. 
However in the first part of the study the fractional recovery rate (FRR) of 
13C in carbon dioxide (CO2 ) in children with CRF was determined, as a 
prelude to protein turnover studies. Protein turnover was then measured 
and the effect of rhGH studied. RhGH was prescribed at 4 iu m'2 per day. 
Synchronous blood samples were also obtained for endocrine analysis.
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Patient details are as described in chapter 2, and appendix 2.5 (Table 
4.1).
None of the patients were on a protein restricted diet, and their intake 
was greater than 3 g/kg/day. They underwent regular assessment by a 
dietician to ensure that their caloric intake was adequate.
Each study was conducted in the fasting state (within 12-18 hours of last 
meal consumption), with no intake permitted from midnight on the eve of 
the study, except for water. Patients were instructed not to take any 
medications until the study had been completed. Children on steroid 
treatment received alternate day prednisolone and therefore took their 
medication at least 24 hrs prior to the commencement of the study.
Height was measured using an upright Harpenden stadiometer 
(Harpenden Ltd, Crymych, UK), whilst weighing was carried out using a 
digital display scale (SECA, UK). Anthropometry was performed using 
Holtain calipers (Holtain, UK) to obtain subscapular and triceps skinfold 
thickness, with measurements checked twice for accuracy, and 
averaged. Mid-arm circumference (mid-point of shoulder tip and 
olecrenon) was obtained using a non-distendable tape measure. The left 
arm was used on all occasions in each individual, with the arm relaxed 
and hanging down. After their height and weight had been measured, 
bed rest was commenced.
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Height (Ht) standard deviation scores (SDS) were calculated using 
reference values obtained from normal, age matched children (10).
1-13C-Leucine was the tracer used for the reasons discussed above. It 
has been used extensively in studies involving adult subjects (healthy, 
with renal failure or endocrine abnormalities) (180, 203,205, 207) and 
children (188,212).
4.4.1 Fractional recovery of 13C-bicarbonate in children 
with chronic renal disease
Baseline breath samples were obtained, before a priming bolus of 1-13C 
bicarbonate was administered at 2mg/kg via an indwelling intravenous 
catheter, immediately after which an infusion was commenced to deliver 
2mg/kg/hour of the isotope. The infusion was prepared on the study day 
using the weight obtained. Stable isotope was obtained in powder form 
from the Isotope Labs, Cambridge, Andover, USA and converted into 
sterile solution with a 99% enrichment (confirmed by Gas 
Chromatography Mass Spectrometry) of 1-13C Bicarbonate by the Stable 
Isotope Services of Northwick Park Hospital Pharmacy, London. Further
114
sampling then occurred at 1.0, 2.0, 2.5, 2.75, 3.0, 3.25, 3.5 hours into the 
study (Table 4.2).
Breath samples were collected by exhalation into a modified one way 
PVC bag with one inlet and one outlet valve from which 20 ml samples 
were aspirated and injected into vacutainer tubes for storage until 
analysis. Both the bag and the syringe were “washed out” twice, 
immediately before each sample collection, by exhalation into the bag by 
the subject with disposal of the expired air.
Indirect calorimetry was performed with the Deltatrac II machine 
(Deltatrac II, Datex, Finland) in an open circuit mode 1-1V2 after isotope 
infusion was commenced. The machine was calibrated on each 
occasion prior to usage after a “warm up” period of half an hour, with O2 
and CO 2 cylinders (Vickers, UK). The transparent hood and canopy were 
placed over the child’s head and shoulders and secured to permit no 
leakage. One end of the canopy was attached to the Deltatrac via a 
plastic elephant tube, whilst the other end was attached to a free ending 
tube through which air entered the hood and was drawn from here into 
the machine. Minute readings commenced from when a steady state 
(approximately after 5 minutes) with less than 10% fluctuation in 
consecutive readings showed on the monitor. Readings were obtained 
for a minimum of twenty minutes, ideally 40 min or longer if tolerated 
without the child becoming restless or falling asleep. Values were
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obtained for the minute volume CO 2 produced and O2 consumed. Using 
these the respiratory quotient (RQ) and resting energy expenditure 
(REE) were calculated by the software on the Deltatrac (215), based on 
the child’s age and auxology which was recorded at the beginning of 
each session on the Deltatrac.
4.4.2 Leucine Studies
The protocol here was designed to determine protein turnover before and 
after rhGH. Eight patients completed all studies. Patients had a baseline 
study, which was then repeated after two months of rhGH treatment 
(figure 4.3). Four patients (two with CRF) selected randomly (by a “blind 
observer) went on to participate in a further study three months after the 
second one in order to obtain further information about the “longer” term 
effects of rhGH. No distinction was made for gender, nor renal status 
(CRF or renal transplant) in view of the small number of patients.
Practically the study differed from the fractional recovery studies above 
only in that 1-13C-leucine was administered both as a priming bolus of 
1 mg/kg and an infusion of 1 mg/kg/hr. 13C-Bicarbonate was administered 
as a bolus only, of 1 mg/kg, to prime the HCO3 ~ pool (Table 4.2). Use of 
priming doses reduces the time taken to reach steady state.
116
Breath samples, as described above, as well as blood samples to 
determine the concentration and enrichment of 1-13C-a ketoioscaproic 
acid (KIC), the metabolite produced by reversible transamination of 
leucine, were collected simultaneously. A second cannula inserted into 
the contralateral hand at the same time as that inserted for the infusion 
was used to obtain blood samples.
Blood samples for endocrine investigations were also collected when 
baseline enrichment samples (Table 4.2) were obtained, and analysed 
for GH, IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3, insulin, c-peptide, 
ALS and IGF bioactivity. Total serum CO2 , a measure of acid-base 
balance, and cortisol levels were also determined.
All stable isotope blood samples were placed on ice for transportation to 
the laboratory where they were centrifuged for 5 minutes at 3000 
revs/min. The supernatant was pipetted into sterile tubes and frozen at - 
70° C until analysed.
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4.4.3 Calculations
4.4.3.1 Anthropometries
Triceps skinfold thickness and mid-arm muscle circumference (MAC) 
(Table 4.3) were used to calculate approximations of cross sectional fat 
and muscle using the equations (216):
muscle (mm2) = (MAC - [n S] )2/  (47i) 
fat (mm2) = (S * MAC/ 2) + ( n S2/4)
where MAC is the mid-arm circumference in mm, S is the triceps skinfold 
thickness in mm. and from these equations a ratio of fat: muscle was 
derived. In adults there can be 15-25% overestimation in arm muscle 
area and 10% in fat area by anthropometry as confirmed by 
computerised tomography (217).
Body mass index (BMI) was calculated using the equation
BMI = weight (kg) /height2 (m)
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BMI was compared to gender based reference curves derived in 1990 
from normal British children (155).
Resting energy expenditure (REE) was calculated during indirect 
calorimetry by the REE software (215) on the Deltatrac II machine from 
the minute volume O2 consumed and CO 2 produced by the children.
4.4.3.2 Stable isotope calculations
Enrichment values were plotted to obtain graphs (figure 4.4) showing 
variation with time. From these plateaus of enrichment during the steady 
state period were obtained and the mean of the points was used in 
calculations of protein kinetics as described below. A plateau was 
defined as an area on the graph that showed a curve parallel to the axis 
on which time was plotted, indicating no increase in enrichment with time. 
There was less than 10% fluctuation of the points in this region about the 
mean derived from a minimum of 3 adjacent points for 13C KIC, with less 
than 5% fluctuation about the mean for 13C 0 2.
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4.4.3.2.1 Fractional recovery (FRR) of 13C
The minute volume of expired CO 2 (VC02)was obtained by indirect 
calorimetry, and the rate of appearance (Ra) of the label in it can be 
calculated from the following equation:
Ra = F { (E / E C 02)-1} 
where F is the rate of infusion of the labelled sodium bicarbonate 
(pmol/min); Ej is the enrichment of the infusion (atoms % excess- APE) 
and E CO 2 the enrichment of expired CO 2 (APE).
4.4.3.2.2 Protein kinetics
During steady state the rate of appearance of the amino acid in the 
plasma pool is equal to its rate of disappearance and reflects the protein 
turnover rate or flux (F). Entry into the pool occurs due to protein 
catabolism (C) and ingestion (I), whilst removal is due to protein 
synthesis (S) and non reversible oxidation (O). This can be equated:
F = C + l = S + 0
In the postabsorptive state, no ingestion takes place, and therefore
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F = C = S + O
(In some studies but not all, the quantity of leucine infused is subtracted 
from the flux to calculate catabolism. In present study this amounted to 
approximately 0 .1-0 .12 pmol/kg/min of leucine, or 0.3g/kg/day of protein. 
This was not subtracted from any of the calculations of flux and 
synthesis)
Using the enrichment of C 02  in breath, the rate of oxidation can be 
determined as follows:
F 13C 0 2 is the CO2  production rate by 13C-leucine oxidation (pmol/kg/hr);
Ei = enrichment of infused leucine (APE); and Ep = enrichment of plasma 
at steady state.
Fl3C 0 2 is calculated from:
F13C 0 2= F C 0 2E C 0 2/W  (60*41.6/ [ 100*0.81])
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E CO2 is the mean enrichment of expired breath at steady state; FCO2 is 
the CO2 production rate (l/min); W= weight of subject (kg); 60 (min/hr) 
and 41.6 (fimol/l) converts FCO2 to ^mol/hr; 100 changes APE from a 
percentage to a fraction and 0.81 is the corrective factor that accounts for 
the fractional recovery of 13C from the oxidation of 13C-leucine.
The flux/turnover can be determined by the dilution of the 13C-leucine 
infusion in plasma once the steady state is reached, using the following 
equation:
Q = i [ (Ei/ Ep)-1]
where Q= flux/turnover; i = 1-13C-leucine infusion rate (^mol/kg/hr); Ei = 
enrichment of infused leucine (APE); and Ep = enrichment of plasma at 
steady state.
Net balance is derived from the subtraction of rate of appearance 
(protein degradation) of amino acid in plasma from rate of disappearance 
(synthesis). Therefore
Net balance = synthesis- flux
(as flux is equal to protein degradation in studies during the fasting 
state)
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The figure 590 was used to convert leucine into protein (590pmol leucine/ 
g protein).
4.4.4 Sample Analyses
4.4.4.1 Breath
These were analysed in batches by a commercial firm (BSIA, London) 
using an isotope ratio mass spectrometer (IRMS). The principle of this is 
that the sample is introduced into the vacuum chamber of the 
spectrometer, with bombardment by electrons generated from a filament 
wire which induces a positive charge on the sample molecules. By a 
combination of repulsion using electrodes, and deflection with magnets, 
the molecules can be separated on the basis of their mass. Detection 
plates quantify the different isotopes of the gas.
Calibration of the samples in the IRMS can be carried out using a 
reference gas with a known enrichment.
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4.4.4.2 Leucine / Ketoisocaproic acid
Blood samples were used to determine plasma enrichment. Although 1- 
13C-leucine was infused, the enrichment of its metabolite, 1-13C-a  
ketoisocaproic acid (13C-KIC) was determined as this is a more accurate 
reflection of intracellular events where protein synthesis/ oxidation occurs
(213). Enrichment is determined by gas-chromatography mass 
spectrometry (GCMS). Samples were analysed by the stable isotope unit 
at Dundee University, UK.
13C-KIC is derivatised to its more volatile forms-O-phenylenediamine 
(OPD) and tert-butyldimethylsilyl-methylfluoroacetamide (MtBSTFA).
This is then injected into the GCMS and vaporised on entry at a temp of 
250° C. The vaporised sample is swept by inert gas (helium, hydrogen, 
nitrogen, methane) through the chamber into a column that is coated with 
a non-volatile liquid. Here some of the sample will elute before entering 
the separator at the interface between the gas chromatography and 
ionisation chamber of the mass spectrometer (MS). The separator 
reduces the pressure of the “gases”, and also ensures that more of the 
sample and less of the inert gas enters the MS.
Enrichment of the infusates was confirmed by GCMS of the solutions, 
and compared with internal standards deuterium labelled leucine and 
deuterium labelled KIC (d-leucine and d-KIC).
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4.4.4.3 Endocrine
Samples were batched and analysed by an experienced technician using 
commercially available kits manufactured by Diagnostic Systems 
Laboratory (Texas) for all assays except GH (J. Jones), IGF-I (J. Jones), 
IGF bioactivity (Dr Taylor). The methodology is as described in chapter 3.
Cortisol was analysed by competitive immunoassay procedure by the lab 
staff using a kit provided by Diagnostic Products Corporation.
TCO2 was analysed by lab staff as part of the routine clinical monitoring 
of the children.
4.4.5 Statistics
The Wilcoxon rank test was used to determine significant differences 
between paired samples, before and after rhGH was commenced. Due 
to the small number of patients completing all the studies, subdivision 
into groups on the basis of the interval between the first and second 
leucine isotope study for statistical analysis was not possible . 
Spearman's test was used to determine correlations between the 
different parameters (flux, synthesis, oxidation, arm muscle area, cross
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sectional fat area, BMI, weight, Ht SDS, insulin, REE, Gh, cortisol, IGF-I, 
IGFBP-1, IGFBP-3 and IGF bioactivity) before and after rhGH. Guidance 
was obtained from Ms J Thompson about the appropriate statistical tests 
to be used.
4.5 Results
For statistical analysis, results for the CRF and transplanted patients 
were pooled due the small number of patients. The transplanted 
children, with the exception of one patient (Patient d) had CRF of their 
graft thus minimising clinical differences between the groups. It was not 
possible to recruit more children to the study to which clinical indication 
for, and consent to use of rhGH by the family and patient was a criteria.
4.5.1 Anthropometric changes
Table 4.5 shows the cross sectional area of fat and muscle, and the ratio 
of fat: muscle in the individual patients, before and after the use of rhGH. 
All children showed a decrease in the fat: muscle ratio with the use of 
rhGH. Patients a,c,f,h are children with CRF, whilst b,d,e,g are those with 
a renal transplant. The cross sectional fat area in the transplanted 
children is approximately four times that of the CRF patients, whilst the 
muscle area is approximately 1.5 times greater in the transplanted group
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(based on median values for the groups). The muscle area in the CRF 
group increased by 35%, whilst that of the transplanted group increased 
by 11%. Similarly the fat area in the CRF showed a larger decrease of 
19% whilst that of the transplanted children dropped by 13%. Statistically 
the muscle area before and after the use of rhGH differed significantly 
(p=0.02), whilst the fat:muscle ratio also showed a significant difference 
(p=0.01). There was no difference in fat area.
4.5.2 Changes in weight, body mass index (BMI) and 
resting energy expenditure (REE) with rhGH
There was no significant alteration in the weight (figure 4.5, Table 4.5) of 
the children before or after the use of rhGH. The transplanted children 
were heavier than the CRF patients, but it was not possible to confirm 
this statistically due to the small number of patients.
The BMI of the children did not change significantly with use of rhGH, but 
was lower in the CRF group than the transplanted group (figure 4.6,
Table 4.5). BMI for the former group generally was below the 50th centile 
with one exception, which was closer to the 90th centile. The BMI for the 
transplanted group was predominantly located between the 75th and 91st 
centiles, with that of one patient closer to the 99th centile.
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All the children showed an increase in REE with use of rhGH, which was 
significant (p=0.01) (figure 4.7, Table 4.5). The median REE for the 
transplanted group was lower than that of the CRF group before rhGH, 
but this increased to equal that of the CRF group with rhGH therapy.
The respiratory quotient (RQ) of the children was low at 0.78 (median 
value) and this decreased, but not significantly, to 0.74 with rhGH use 
(Table 4.6). RQ is the ratio of oxygen consumption to carbon dioxide 
production and reflects substrate oxidation. Carbohydrate oxidation is 
indicated by higher RQ than fat oxidation (218). Therefore the patients in 
this study were metabolising fat more than carbohydrate and this 
increased with use of rhGH.
4.5.3 Fractional recovery of 13C-bicarbonate
Of the 12 children studied, four dropped out and did not proceed to the 
protein turnover studies.
The fractional recovery of 1-13C ranged from 53% to 85%, with higher 
recovery obtained for the children with CRF generally than transplant as 
shown in Table 4.4. Variability in the fractional recovery arises from CO2  
“fixation” in slowly turning over pools.
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4.5.4 Protein turnover, growth and endocrine factors 
before and after use of rhGH
IGF-I SDS and IGFBP-3 SDS were calculated as described in the 
previous chapter. IGF-I and IGFBP-3 combined are more representative 
of GH activity than either peptide individually (148, 219).
Table 4.6 and figures 4.8 and 4.9 show the results obtained for each 
patient for protein flux and synthesis before and after the use of rhGH. 
Table 4.7 shows the protein flux and oxidation in (amol/kg/min for 
comparison with historical work in a similar group of patients (211). Flux 
and synthesis were higher in those with CRF rather than the renal 
transplant group, but could not be confirmed by statistical analysis due to 
the small numbers. The difference between the groups was not as 
noticeable for oxidation figures. Changes in indices with the use of rhGH 
differed. Most of the patients showed a rise in flux with use of rhGH, 
whilst the change in synthesis was more variable as 3 patients (2 CRF) 
had a decrease in the rate of synthesis with use of rhGH. Similarly the 
response noted in the endocrine parameters varied.
Figures 4.10 (i)- 4.17 (ii) show the trend in endocrine factors, flux, 
synthesis and percentage of leucine synthesis : flux at baseline and after 
use of rhGH. Figures represent data on each patient individually, and
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have been divided between parameters with low (i) and high values (ii) to 
enable clarity. IGF-I, IGFBP-3 and c-peptide values have been divided 
by 10 to enable better scaling. Children who were monitored over 5 
months of rhGH treatment (patients e,f,g,h) show three time points (time 
0,2,5) on their figures, permitting monitoring of the effects of continued 
rhGH. Most children showed a consistent response to rhGH, with a rise 
in IGF-I levels, IGFBP-3 and ALS. In some insulin and c-peptide also 
rose, but in two patients the response of insulin and c-peptide was not 
synchronous, in that whilst c-peptide rose, insulin levels dropped. C- 
peptide accumulates with reductions in GFR as it is dependent on renal 
clearance, unlike insulin which is metabolised by the liver.
Changes in percentage of leucine flux being incorporated into leucine 
seemed to follow the trend of IGF-I I more than IGF-I in most cases, 
except for patient g where the percentage synthesis decreased, whilst 
IGF-II rose. However, IGFBP-3 also rose noticeably. Interestingly at this 
point the TC 02of the patient had dropped to 17 from 19 mmol/l.
Effects of rhGH with time seemed to wane as the initial post rhGH 
response produced a steeper slope, which became flatter between the 
second and third observation for IGF-I, ALS, insulin and IGFBP-3.
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Table 4.6(i-v) shows the median values and range of protein turnover, 
growth parameters and endocrine factors before and after 
commencement of rhGH.
Median values of all parameters except IGFBP-1 showed an increase 
with use of rhGH. However this was significant only for IGFBP-3 SDS (p=
0.01), GH (p=0.02) and Ht Vel SDS (p=0.03) and c-peptide (p=0.05).
Figure 4.18 shows the changes in Ht SDS, and figure 4.19 shows the Ht 
Vel SDS in all children before and after use of rhGH. Although for the 
majority of patients both parameters appear to increase, no significance 
can be attached to this as the observation period was short.
4.5.5 Correlations between protein kinetics, body 
composition, and auxological parameters
4.5.5.1 Pre RhGH (table 4.8)
IGF-II correlated with cross-sectional arm muscle area (r=0.833, p=0.01), 
BMI (r=0.802, p=0.02), and weight (r=0.833, p=0.01). IGF-II also 
correlated with the percentage of leucine incorporated into protein 
synthesis (r=0.708, p=0.05), indicating that that higher levels of IGF-II
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may lead to increases in protein synthesis. The exact role of IGF-II in 
growth in postnatal life remains unclarified, but levels are low in GH 
deficiency and increase with rhGH treatment (107).
Insulin correlated directly, but just losing significance, with fat (r=0.667, 
p=0.07).
GH levels had an inverse correlation with REE (r=-0.81, p=0.02). This 
relationship is complicated by acidosis and the use of steroids, both of 
which increase REE (220), but decrease GH production (97). GH levels 
correlated with the ratio of synthesis : flux (r=0.781,p=0.02) A direct 
correlation between GH and Ht SDS was present (r=0.667, p=0.07), but 
just lost significance.
Cortisol levels also correlated strongly with Ht SDS (r=0.893, p=0.007), 
and with GH levels (r=0.750, p=0.05). Physiological cortisol levels are 
necessary to maintain GH receptor expression and growth (152). The 
correlation of cortisol with IGF-I was negative (r=-0.786, p=0.04). This 
may be a reflection of the stimulatory effect of cortisol on IGFBP-1 mRNA 
during low levels of insulin (115) and in CRF there is decreased insulin 
action due to resistance, but cortisol also reduces production of local 
IGF-I (152). A direct correlation of cortisol with IGFBP-1 (r=0.893, 
p=0.007) was present. A significant inverse correlation of IGFBP-1 with 
IGF bioactivity (r=-0.829, p=0.04) was present.
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4.5.5.2 Post rhGH therapy (table 4.9)
Both flux and synthesis correlated negatively with both IGF-I (r=>-0.762, 
p<0.03) and with GH levels (r=-0.738, p=0.04). Oxidation also correlated 
inversely with IGF-I, but just missed being significant (r=-0.690, p=0.06). 
GH and IGF-I increase synthesis, but in uraemia, particularly in the 
presence of acidosis or use of steroids, the normal relationships are 
attenuated. Differences between pre and post rhGH levels of TCO 2 
correlated directly with differences in the synthesis : flux ratio (r=0.840, 
p=0.009) showing that acid-base balance influences the amount of 
leucine released by catabolism incorporated into synthesis.
The correlation of IGF-II with muscle area was no longer significant 
(r=0.643, p=0.09). The correlation of IGF-II with REE occurred but just 
missed being significant (r=0.690, p=0.06). Weight also correlated with 
REE (r=0.714, p=0.05), as did muscle with REE, with loss of significance 
(r=0.667, p=0.07).
A negative correlation of muscle area was observed with the difference 
in Ht SDS after and before rhGH treatment (r=-0.714, p=0.05). Thus 
increases in linear length with treatment is associated with lower cross 
sectional muscle area.
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TCO 2 , a measure of acid-base balance, correlated negatively with insulin 
levels, (r=-0.766, p=0.01). Acidosis reduces the efficacy of insulin. 
Differences in TCO 2 and in ratio of leucine synthesis to flux correlated 
negatively before and after rhGH (R=-0.840, p=0.009). Increasing 
acidosis leads to decreased leucine incorporation into protein synthesis.
4.6 Discussion
4.6.1 Protein turnover
Protein kinetics are higher in healthy children than adults (179, 208), but 
can be altered by illness, drugs, nutritional state and hormones. More 
information on protein kinetics is available in adults than in children, 
particularly in chronic illnesses. Skeletal muscle is the largest reservoir 
of protein in the body, and therefore in patients with CRF where lean 
body mass can be reduced (181) protein turnover will be affected (182, 
191, 221). Information on lean body mass in children with CRF is limited 
but shows that this can be reduced (176, 221), and growth is suppressed 
in these patients (71, 72). To some extent this can be due to suboptimal 
caloric intake (193, 221). However endocrine imbalances (see below)
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and metabolic acidosis (180, 183) will also affect growth and protein 
turnover.
The study of protein turnover in this thesis has been performed in 
children with both CRF and those post-renal transplant. There are 
several potentially important limiting factors to interpretation of the results 
such as the differential time interval between repeat studies. Growth 
monitoring over a short term (£ 3 months) can also be inaccurate. Due 
to the criteria of clinical indication for the use of rhGH for recruitment to 
the study, numbers were limited and it was not possible to control for 
age, gender or pubertal development. The age of these children, only 
one of whom was female, ranged from 1 0 - 1 6  yrs. The median 
pubertal stage for the group was 2 with none of the children at stage 3+. 
Results from protein turnover studies performed in adolescents are not 
available, and therefore it is not possible to comment on the effects of 
puberty, whilst an age related decrease in protein synthesis has been 
noted. Logically it would be expected that protein turnover would increase 
in line with the growth spurt.
Thus the group studied here is heterogeneous and although this can 
potentially influence results, the probability of this is low as discussed 
above and for the following reasons:
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I. Data from other studies (235) suggest that after commencing rhGH, 
changes in metabolic rate are maximal by 6 weeks with little 
alteration noted thereafter. The work carried out here corroborates 
this as no obvious difference was apparent between the studies 
performed at 2 or 3 months.
II. The transplanted children were on alternate day, low dose steroids 
which have minimal systemic side effects (59) and thus might not be 
expected to greatly influence their metabolism, including protein 
turnover. These patients however would previously have received 
high dose steroids and this can influence lean body mass and body 
fat. This has been discussed further below.
III. Children in previous protein turnover studies have not been divided 
on the basis of gender and there is no data to suggest that in 
prepubertal females the protein flux will differ from that of age 
matched males.
IV. The influence of age is discussed further below.
The protein flux of the CRF patients in the study was comparable to that 
observed in healthy children (187,188), but higher than that of the 
children who had undergone a renal transplant and were on steroids.
Due to the variation in fractional recovery of 13C in breath samples from 
the patients, the conventionally accepted figure of 0.81 was used as the 
correction factor in calculations to enable comparison between the
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protein turnover results from this study and those from others. This 
correction factor has been validated in many studies involving adult 
subjects (205, 207) and is used in adults with CRF (181), and children 
with (211) and without CRF (188). The transplanted group had higher 
BMI than the CRF group, phenotypically had more fat and a greater fat: 
muscle ratio. Few studies of protein turnover base their results on fat free 
mass, using body weight (kg) instead, but higher rates of protein turnover 
have been obtained with adjustments for lean body mass in CRF (211). 
However in healthy, obese children protein kinetics are higher than in 
non-obese children, and when adjusted for fat free mass, differences 
between obese and lean children disappear (222). In these children it 
appears that although adipose tissue is increased, there is a concomitant 
increase in lean body mass and REE is higher than in non-obese 
children (223, 224). Protein metabolism occurs predominantly in skeletal 
muscle which represents 70% of the lean body mass, but also in organs 
such as the kidney (225). A contribution of adipose tissue to 
phenylalanine kinetics has been found in one study, which may indicate 
some contribution of adipose tissue to protein turnover (226). In the 
patients here it appears that whilst BMI and adipose tissue were higher in 
the transplanted children than CRF, this does not appear to apply to their 
LBM.
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Protein turnover decreases with age (179, 186) and infants have high 
protein turnover (6-7 g/kg/day) (188, 189) compared with adults (179). 
The results of the transplanted group (per kg body weight), who mostly 
were older and pubertal compared with the CRF group, are closer to 
those of healthy adults, whilst that of the CRF group are comparable to 
those observed in younger children with CRF in other studies (211) and 
lie between values observed for adults (187) and infants (188). However 
the results of the transplanted children appear comparable to protein 
kinetics observed in healthy adolescents admitted for corrective surgery 
following injury from burns (186).
Even mild acidosis can stimulate activity of branched chain keto-acid 
dehydrogenase in muscle (208), with increased protein degradation (185, 
211) and metabolism of branched chain amino acids in uraemia (194).
An inverse correlation between protein degradation, when corrected for 
lean body mass, and acidosis has been reported by Boirie (211), but was 
not observed in this study, perhaps as protein turnover was not corrected 
for lean body mass and patient numbers were small. The TCO 2 levels, a 
measure of acid-base balance in the patients, were at the lower end of 
the normal range (20 - 26 mmol/l) as shown in table 4.6. Patients who 
had levels at or below the normal range showed an increase in oxidation, 
with either no change in flux and synthesis or an increase in the former 
and a decrease in the latter with use of rhGH. The influence of acidosis
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on protein turnover was confirmed by the direct correlation of differences 
in TCO 2 with differences in synthesis to flux ratio with use of rhGH. One 
patient had a 9 am cortisol level that clearly would be considered 
subnormal, and in this patient synthesis and flux increased whilst 
oxidation decreased. The effects of acidosis appear to be mediated, to 
some extent, by glucocorticoids, as protein degradation and oxidation in 
adrenalectomized animals, when acidotic, do not differ from normal 
controls until given dexamethasone (185). Steroids increase catabolism 
and oxidation in adults and animals (157,185, 227) with increased 
turnover of non-essential amino acids (228) and REE (220). Marked 
muscle wasting is present in patients with Cushing’s Disease when 
endogenous cortisol levels are excessive (229) and chronic acidosis can 
elevate cortisol levels (185). There was an inverse correlation of TCO 2 
with insulin levels before use of rhGH. Insulin has antiproteolytic actions 
(94), and elevation of insulin levels in acidosis is consistent with 
resistance to the actions of insulin.
Use of rhGH produced differing responses in the patients, but the median 
values for flux, synthesis and oxidation showed an increase of 3.3%, 
4.1% and 2.5% respectively from baseline. The median cross sectional 
arm muscle area of the children increased (8%) significantly and cross 
sectional fat:muscle ratio decreased significantly with use of rhGH, with a 
23 % decrease in cross sectional adipose tissue observed. Greater
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increases in lipolysis (21%) than protein synthesis (11%) have been 
documented by others as well with use of rhGH (190) with more rapid 
changes in adipose tissue than muscle observed (230). A major reason 
for the discrepancy between the results of the isotope studies and 
anthropometric findings is that that the isotope studies were conducted in 
the fasting state which a not a common physiological state. 
Anthropometric findings represent prolonged observations over various 
physiological states. Fasting in normal individuals is associated with 
increased oxidation, and decreased synthesis, whilst the effect on protein 
catabolism remains controversial (179). In CRF these protein kinetics are 
exaggerated and fasting, uremic rats show an attenuated response with 
greater weight loss, protein degradation and oxidation than control 
animals (184, 192). It is interesting to speculate that this “exaggerated 
response” is a manifestation of inefficient metabolism of substrates such 
as ketones originating from adipose tissue which is the main fuel source 
as determined from the low RQ of 0.78 (discussed further below), with a 
detrimental effect on acid-base balance resulting in further catabolism. 
Use of rhGH, which has lipolytic actions, would exacerbate these 
findings, and would explain why Garibotto observed increased 
metabolism of branched chain amino acids (194) as fuels alternative to 
fat are metabolised. In normal individuals insulin levels are low during 
fasting and IGF action may enhance substrate metabolism. IGF-I levels 
are also decreased by fasting. In patients with CRF IGF actions are
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inhibited by an excess of IGFBPs and insulin resistance is also present. 
Feeding results in increased muscle and whole body protein synthesis, 
and increased oxidation of amino acids (203, 231).
Effects of feeding on protein degradation vary, with either no change 
(203) or a decrease in catabolism (231). The lack of inter and intra 
individual consistency in studies here can be attributed to three 
observations from other studies: i) An inter individual physiological 
variation of 10% observed even in health (186, 232) and within 
individuals (3-6% for flux and synthesis) (179); ii) Whole body protein 
kinetics were measured which shows less change with intervention (203, 
205) and are lower than skeletal muscle turnover which accounts for 40%  
of protein synthesis in the body (203, 225). Other studies conducted in 
adults with CRF in which rhGH was used measured forearm muscle 
turnover (191). iii) In CRF factors such as acidosis and uraemia 
attenuate the response to the anabolic hormones (insulin, GH and IGF-I) 
(180). RhGH in adults with GH deficiency, uraemia and normal controls 
causes an increase in protein synthesis, does not alter degradation, 
reduces oxidation and has a lipolytic effect leading to decreases in 
adipose tissue (157, 190, 191,233, 234). In the present study, children 
with normal TCO 2 levels showed a rise in protein synthesis with use of 
rhGH. GH may have a direct influence on protein turnover (191, 234), 
although many of its actions are mediated by IGF-I, and use of rhGH
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results in increased insulin levels (81). The increase in muscle area was 
mirrored by significant rises in REE (see figure 4.7) of all children. An 
increase in energy expenditure with the use of rhGH in children has also 
been found previously (235).
The change in IGF-I SDS with the use of rhGH was not consistent in all 
children, and did not correspond to changes in protein turnover. This 
suggests that IGF-I mediates some of the actions of GH but not all as 
also observed in animal studies (236). IGF-I has a direct influence on 
turnover (227, 237) and decreases protein catabolism and oxidation 
(237). In uraemic animals (238) and healthy adults (237) a dose 
dependent effect has been shown with no significant effect of low dose 
IGF-I on protein kinetics, whilst high dose IGF-I increased protein 
synthesis and decreased oxidation. Addition of prednisolone to IGF-I 
administration increases proteolysis and oxidation but does not alter 
synthesis (227). In CRF, IGF-I activity is affected by reduced renal 
clearance of IGFBPs, and there is some evidence of defects in post 
receptor phosphorylation with increased IGF-I receptor mRNA expression 
and numbers compared to normal in animal studies (238).
Insulin also has anabolic actions, consisting mainly of inhibition of protein 
degradation and lipolysis (239). However there appears to be some 
conflict between findings in animal and human studies with regard to its
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actions on stimulating protein synthesis, which has been demonstrated in 
the former (240) but not latter (233, 239, 241), and in fact in one study 
involving diabetics, insulin inhibited protein synthesis, albeit less than 
degradation and oxidation (205). In the present study no relation was 
observed between insulin/ c-peptide and the markers of protein turnover 
either before or after the use of rhGH, despite the significant increase in 
c-peptide levels. Insulin did however correlate with cross-sectional areas 
of both muscle and fat before rhGH treatment. Resistance to the actions 
of insulin is well recognised in CRF (174), with use of steroids (157) and 
obesity (242) into which category some of the children come close to 
(BMI> 98th centile), and thus may explain the lack of observed 
association between proteolysis and insulin. The mechanism of 
resistance to insulin in CRF appears to be a combination of inhibition of 
insulin actions by acidosis (174), binding to a relatively newly described 
peptide (IGFBP-7) (243), binding to the NH2-terminal fragment of IGFBP- 
3 (243), both of which accumulate in CRF, and some degree of post 
receptor abnormality (174). There is an overlap in the actions of IGF-I 
and insulin which have 50% structural homology with cross-stimulation of 
receptors observed (132). Dose dependent responses in protein turnover 
to insulin and IGF-I have been observed (237).
The observed correlations in the present study of IGF-II with muscle 
area, BMI, weight indicate a role for it in protein turnover and growth,
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which has been established in antenatal life but not postnatally. 
Concentrations increased with rhGH treatment, but did not reach 
significance. IGF-II can stimulate insulin receptors, with greater affinity 
than IGF-I, and thus have insulin type actions (134) but also stimulates 
the IGF type 1 receptor which mediates the actions of IGF-I (134).
In healthy individuals it has been found that 20 % of the REE arises from 
protein oxidation, compared to 15 % in patients with CRF who are 
malnourished, but with no observed difference in total REE between the 
two groups (214). Fat oxidation was higher in these CRF patients than 
healthy subjects, with a reduction in total body fat. The median 
respiratory quotient (RQ) obtained approximately 2 hr into the study from 
our patients was 0.78, which is lower than that in Schneweiss’s study
(214), and is more indicative of starvation and fat metabolism. The RQ 
decreased further in most of our patients with rhGH therapy, non 
significantly to 0.74, as would be expected with increased fat metabolism.
4.6.2 Growth and Endocrine changes with use of rhGH
Short stature is emerging as a major complication in adults with onset of 
CRF in childhood (34, 59). Use of rhGH shows improvement in Ht SDS 
(72, 75), and this was evident in 5 study patients rather than all, but 
maybe confounded by the short interval between observations which
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can make measurements unreliable (7). Measurements of height 
velocity (Ht Vel SDS) suggest that the rate of growth improved 
significantly in all patients except one (bearing in mind the short term 
between observations). The response of children with CRF to rhGH is 
not as marked when compared to short normal children (193), and this 
blunted response maybe attributed to endocrine, metabolic and 
nutritional abnormalities. The mode of administration of rhGH, a single 
bolus compared to the endogenous nocturnal pulses, may also be 
influential as the rate of increase of levels is more important than 
duration of exposure to GH in determining the magnitude of the response 
(80). This may explain to some extent why children with CRF in whom 
GH levels are elevated, exogenous GH administered once daily show 
less improvement in growth rate than those with normal levels.
The mechanism by which short stature arises has been discussed in 
chapter 3. The importance of GH was confirmed by the correlation with 
Ht SDS in the patients before use of rhGH. In children with CRF GH 
levels can be elevated (137, 138) or reduced by steroid treatment (139). 
GH levels were not elevated in the children with CRF, nor reduced in 
those with a transplant as determined by a single, fasting 9 am sample, 
but IGF-I SDS were low or in the low - normal range in some patients, 
perhaps a manifestation of the resistance to the actions of GH observed 
in CRF. Administration of high dose rhGH (4iu.m'2 daily) produced no
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significant improvement in IGF-I SDS, unlike other reported studies (71, 
75, 199, 201) where the observation period was over 3 months. Unlike 
IGF-I SDS a consistent increase of IGFBP-3 SDS in all patients to rhGH 
therapy was observed which was significant. This increment has been 
shown to be due to increased production of the intact molecule in CRF 
and thus has a positive role in growth promotion (170). RhGH also 
enhances growth by decreasing IGFBP-1 levels (191), the mechanism of 
which is perhaps of suppression by increased insulin and IGF-I levels. 
However the observed decrease in IGFBP-1 levels in the present study 
was not significant.
Tolerance to the effects of rhGH appears to occur with long term use, 
and this is most marked when longitudinal growth studies in children are 
conducted (201). Changes in body composition and REE have also been 
shown to be maximal after 6 weeks of treatment, with lower increments 
noted there after (235). Protein deposition requires a rate of synthesis 
above that of degradation, and it appears that there is a time lag between 
increase in synthesis and degradation when a new steady state develops 
(179). The effect of these observations on patients in the time frame of 
the present study is difficult to quantify. Four of the children were 
restudied after a further three months (5 months from commencing rhGH 
treatment). The changes noted in protein turnover, as seen by the 
percentage synthesis to flux ratio, did not appear greatly different from
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those at 2 months with no consistent pattern between the four children. 
The changes seen in IGF-I SDS and IGFBP-3 SDS graphically appeared 
less marked during this time period, whilst there appeared to be no 
overall change in IGFBP-1.
In summary, protein turnover, expressed as whole body weight, and REE 
were higher in patients with CRF than in those children with a renal 
transplant, and were reflective of the amount of lean body mass. Protein 
kinetics determined using stable isotopes are altered by the physiological 
state prevailing during the time of the study only, and during fasting the 
rate of catabolism observed was higher than that of synthesis. The acid- 
base status also influences the amount of leucine being incorporated into 
synthesis as confirmed by the strong correlation of the differences in 
TCO 2 levels and synthesis to flux ratio. The anabolic actions of insulin 
are also altered by acidosis, with a negative correlation of TCO 2 and 
insulin present, and to what extent this influences the previous 
observation is difficult to quantify. The RQ reflects the use of fat 
predominantly as the endogenous substrate during the studies, and this 
particularly in the presence of insulin resistance observed in CRF, will 
contribute to acidosis with increased ketone production resulting in 
further catabolism which may account for the “exaggerated response 
observed in CRF” described in other studies. Use of rhGH did not 
consistently increase the rate of flux and synthesis in individuals due in
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part to the acid-base balance and to variable levels of resistance to the 
differing actions of GH within and between individuals as observed by the 
changes in IGF-I SDS and IGFBP-3 SDS. The effect of rhGH over a 
prolonged period provides more accurate information about changes in 
body composition as both fed and fasting states are incorporated into the 
observation period. REE, muscle area (LBM) and Ht Vel SDS all 
increased significantly, whilst fat area (adipose tissue) decreased with 
use of rhGH. It is important to point out that the time interval between 
repeat studies is short and this limits the significance of the the 
observations. There is evidence over 5 months of tolerance to the actions 
of rhGH with lower responses in endocrine factors. IGF-II appears to 
have a role in increase in lean body mass and growth in the present 
study, and this has not been reported previously.
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Table 4.1: Demographics of patients in fractional recovery of 13C02 study.
Patient Patient Age Gender GFR+ Pubertal Steroids
(yrs) stage (mg/kg/alt d)
a 1 11.6 m 22 1 na
k 2 16.7 m * 2 na
j 3 7.5 m 34 1 na
f 4 11.6 m 12 1 na
c 5 14.8 m 34 3 na
h 6 12.5 m 18 1 na
I 7 15.2 m 20 1 na
m -8 12.0 m 25 1 0.5
e -9 16.0 m 37 3 0.2
g -10 13.8 m 7 3 0.2
d -11 10.8 f 85 1 0.3
b -12 17.1 m 27 3 0.2
median 13.15 25 1 0.2
Patients a-h proceeded to protein turnover studies 
(-Transplant patients) * on dialysis. +mls/min/1.73m-2
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Table 4.2: Format of each stable isotope (1-13C-leucine) study
Time (hr) 0 1 2 2Vz 23/4 3 31/4 31/2
Bolus (H13C 0 3' ± 
1-13C-leucine) V X X X X X X X
Infusion (H1>jC 0 3 '
or .
1-13C- leucine)
Blood sample 
(enrichment) V V V V V V
Breath sample V V V V V V V V
Blood sample 
(endocrine)
V X X X X X X X
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Table 4.3: Triceps skinfold thickness and mid-arm muscle
circumference (MAC) pre and post rhGH
Patient Triceps (mm)
pre rhGH (post rhGH)
a 10.0 (8.0)
c 12.2 911.6)
f 7.0 (6.0)
h 7.8 (5.8)
b 23.0 (17.0)
d 24.0 (16.0)
e 32.0 (30.0)
g 21.0 (22.2)
median 16.6 (13.8)
MAC (mm)
pre rhGH (post rhGH)
175.0 (180.0)
275.0 (278.0)
174.0 (197.0)
190.0 (210.0)
272.0 (252.0)
249.0 (240.0)
306.0 (334.0)
268.0 (294.0)
258.5 (246.0)
Table 4.4 : Fractional recovery (%) of 1-13C during H13C 0 3- infusion
Patient FRR (CRF) patient FRR (transplant)
a 82
c 53 b #85
f 72 d 64
h 57 e 61
i 67 g 61
k *66 m 73
I 79
median 62 61
*patient on peritoneal dialysis(PD) #patient had been on rhGH for 6months
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Table 4.5 : Anthropometry before and after use of rhGH (post rhGH results *)
Median
BMI BMI* Weight Weight* Fat Fat* Muscle Muscle* REE REE*
kg/m) (kg/m) (kg) (kg) (mm2) (mm2) (mm2) (mm2) ;kcal/day;kcal/da
15.2 15.6 26.1 28.2 953.5 770.0 1641.8 1909.9 944 1336
23.0 23.7 50.0 54.0 1794.3 1718.0 4460.4 4646.4 1017 1384
17.3 16.7 28.5 28.0 647.5 619.3 1840.0 2527.2 1362 1537
17.3 17.7 30.8 33.4 788.8 635.4 2181.0 2928.6 1096 1404
22.3 21.3 48.8 47.4 3543.0 2399.0 3177.7 3121.1 1235 1471
23.2 21.6 34.1 33.4 3440.2 2121.0 2400.6 2867.0 1118 1135
28.7 29.3 61.1 65.3 5699.8 5716.5 3362.9 4578.4 960 1651
24.9 25.6 52.0 54.6 3160.2 3650.3 3250.7 4005.3 1433 1607
22.7 21.5 41.5 40.5 2477.3 1919.5 2789.1 3024.8 1107 1438
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Table 4.5 cont: Anthropometry before and after use of rhGH
(post rhGH results *)
Patient FatiMuscle Fat:Muscle* REE REE*
ratio ratio (kcal/day) (kcal/day)
a 0.60 0.40 944 1336
c 0.40 0.37 1362 1537
f 0.35 0.25 1118 1135
h 0.36 0.21 1433 1607
b 1.11 0.77 1017 1384
d 1.43 0.74 1096 1404
e 1.69 1.25 1235 1471
g 0.97 0.91 960 1651
idian 0.79 0.57 1107 1438
Table 4.6(i): Age and protein turnover before and after use of rhGH (post rhGH results *)
Patient Age Age* Flux Flux* Synthesis Synthesis* Oxidation Oxidation* S:F S:F*
(yrs) (yrs) g/kg/day g/kg/day (g/kg/day) (g/kg/day) (g/kg/day) (g/kg/day) (%) (%)
(leucine synthesis:
a 12.0 12.4 6.05 6.16 5.45 5.36 0.60 0.80 90.0 87.0
c 14.8 15.4 4.95 4.95 4.44 4.40 0.51 0.55 90.0 89.0
f 11.6 11.9 4.89 5.28 4.67 4.67 0.56 0.61 89.0 88.0
h 12.5 12.9 6.65 6.88 6.00 6.16 0.66 0.73 90.0 89.0
b 16.7 17.0 3.69 4.34 3.25 3.81 0.44 0.53 88.0 88.0
d 10.9 11.3 4.34 4.24 3.55 3.66 0.79 0.58 82.0 86.0
e 16.0 16.3 4.36 4.60 3.67 3.93 0.69 0.67 84.0 78.0
g 14.1 14.3 3.77 3.76 3.47 3.31 0.30 0.45 92.0 88.0
median 13.3 13.6 4.63 4.78 4.00 4.17 0.58 0.60 90.0 88.0
% change with use of rhGH 3.2% 4.3% 3.4%
Table 4.6(ii): Endocrine factors before and after use of rhGH (post rhGH results *)
Patient GH GH* ALS ALS* Cortisol Cortisol*
(mu/l) (mu/l) (mcg/ml) (mcg/ml) (nmol/l) (nmol/l)
a 6.8 6.0 23.6 26.8 353 123
c 1.4 3.3 23.0 24.0 178 403
f 1.0 3.1 20.9 20.6 na 185
h 1.8 5.1 20.8 30.8 282 439
b 1.5 7.1 26.8 33.9 155 263
d 0.5 11.6 24.2 20.8 196 282
e 1.1 14.5 29.1 30.8 13 54
g 3.7 14.9 25.0 37.6 293 108
median 1.5 6.6 23.9 28.8 196 224
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Table 4.6(iii): Endocrine factors before and after use of rhGH (post rhGH results *)
patients IGF IGF* IGFBP-1 IGFBP-1* IGF-II IGF-II* IGFBP-2 IGFBP-2
bioactivity bioactivity (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml)
(u/ml) (u/ml)
a 0.07 0.08 165.9 113.4 1082 1113 1220 978
c na 0.89 20.2 47.7 1231 1033 966 790
f 0.25 0.31 94.7 84.2 1230 1290 1028 1086
h 0.59 0.55 93.2 93.7 1191 1251 838 1164
b na 0.51 65.7 43.5 374 719 688 494
d 0.44 na 64.7 96.1 971 1217 310 838
e 0.49 0.84 12.3 5.7 1108 868 364 402
g 0.13 0.10 148.3 55.9 1344 1376 1180 1170
median 0.35 0.51 79.5 70.1 1150 1165 902 908
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Table 4.6(iv): Endocrine factors before and after use of rhGH (post rhGH results *)
Patients Insulin Insulin* C-peptide C-peptide* TC02 TC02* ATC02 A S:F 
(mll/l) (mll/l) (pmol/l) (pmol/l) (mmol/l) (mmol/l) (mmol/l) (%)
a 7.6 14.5 343 756 24 21 -3 -3
c 28.1 17.6 131 585 19 18 -1 -1
f 10.5 7.7 589 393 23 23 0 -1
h 10.8 20.4 530 630 21 23 2 -1
b 5.6 12.3 245 720 20 24 4 0
d 9.3 7.3 134 67 24 26 2 4
e 35.2 55.6 63 1027 21 19 -2 -6
9 8.2 29.3 859 1382 19 17 -2 -4
median 9.9 16.1 294 675 21 22 -1 -1
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Table 4.6(v): IGF-I SDS, IGFBP-3 SDS and Ht SDS 
(post rhGH results *)
Patient IGF-I IGF-I* IGFBP-3 IGFBP-3* Ht Ht*
SDS SDS SDS SDS SDS SDS
a -1.28 -3.32 2.93 4.80 -2.37 -2.16
c 0.67 -0.11 2.94 3.10 -2.45 -3.65
f 0.08 -0.51 3.14 3.21 -2.58 -2.50
h -2.23 0.56 3.21 3.54 -2.41 -3.03
b 0.02 3.29 2.59 5.96 -3.74 -3.33
d -0.98 -0.87 1.26 2.12 -3.26 -2.60
e 0.79 2.68 3.26 3.63 -3.52 -2.25
g -0.82 8.12 3.19 5.14 -2.21 -2.11
median -0.45 0.72 3.04 3.59 -2.52 -2.55
Table 4.7: Flux and oxidation in study patients compared with published results
Patient Flux Oxidation Flux* Oxidation* flux oxidation
pmol/kg/ |jmol/kg/ |jmol/kg/ pmol/kg/ limol/kg/ ymoUkg/
min min min min min min
a 2.48 0.25 2.52 0.33 3.34 0.49
b 1.51 0.18 1.78 0.22 4.96 0.62
c 2.03 0.21 2.03 0..23 3.36 1.06
d 1.78 0.32 1.74 0.24 3.07 0.59
e 1.79 0.28 1.88 0.27 6.42 1.26
f 2.00 0.23 2.16 0.25 2.98 0.84
g 1.54 0.12 1.54 0.18 1.92 0.28
h 2.72 0.27 2.82 0.30 2.20 0.20
2.50 0.61
* post rhGH 2.99 0.59
Figures in bold, italics -  (right hand columns) obtained from literature (ref 211) first 5 children were acidotic.
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Table 4.8: Correlations between protein kinetics, body
composition, and auxological and endocrine 
parameters pre rhGH.
R value P value
Flux: synthesis 0.952 0.001
IGF-II: arm muscle area 0.833 0.01
BMI 0.802 0.02
Weight 0.833 0.01
Ht SDS 0.643 0.09
% leucine synthesis : flux 0.708 0.05
Insulin: muscle 0.643 0.09
fat 0.667 0.07
GH: REE -0.810 0.02
Ratio of synthesis : flux 0.781 0.02
Ht SDS 0.667 0.07
Cortisol: Ht SDS 0.893 0.007
GH 0.750 0.05
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R value P value
Cortisol: IGF-I -0.786 0.04
IGFBP-1 0.893 0.007
C-peptide 0.786 0.04
B M I: Cross sectional fat area 0.738 0.04
Cross sectional muscle area 0.802 0.02
Weight: Cross sectional fat area 0.738 0.04
Cross sectional muscle area 0.929 0.001
IGFBP-1: IGF-I -0.667 0.07
insulin -0.643 0.09
IGF bioactivity -0.829 0.04
Insulin: IGFBP-3 0.643 0.09
IGF bioactivity 0.886 0.02
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Table 4.9: Correlations between protein kinetics, body 
composition, and auxological and endocrine 
parameters with rhGH treatment.
R value P value
Flux: Synthesis 0.976 0.001
Oxidation 0.810 0.02
IGF-I -0.786 0.02
GH -0.738 0.04
Synthesis: IGF-I -0.762 0.03
GH -0.738 0.04
Oxidation: IGF-I -0.690 0.06
IGF-II: Cross sectional muscle area 0.643 0.09
REE 0.690 0.06
BMI: Cross sectional fat area 0.833 0.01
Cross sectional muscle area 0.857 0.007
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R value P value
Weight: Cross sectional fat area 0.833 0.01
Cross sectional muscle area 0.857 0.007
REE 0.714 0.05
REE: Cross sectional muscle area 0.667 0.07
GH: IGF-I levels 0.786 0.02
ALS 0.649 0.08.
ALS: IGF-I 0.743 0.04
IGFBP-3 0.826 0.01
IGF-II: IGFBP-2 0.929 0.001
T C 0 2 : Insulin -0.766 0.01
IGFBP-3: C-peptide 0.810 0.02
AHt SDS: Cross sectional muscle area -0.714 0.05
A T C 0 2 : A percentage synthesis:flux 0.840 0.009
(A represents difference between post and pre rhGH value)
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Figure 4.1: Amino acid turnover and influencing factors :
"Growth hormone, *IGF-I fasting
synthesis
Diet Protein> Amino acid pool
catabolism
Insulin, *IGF- Steroids, acidosis, (fasting CRF)
Oxidation
(increased with steroids, acidosis, fasting) Resistance to actions of hormones in CRF
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Figure 4.2 13C Leucine Kinetics
PROTEIN
SYNTHESIS
13co.
(breath)
Ip tfa c e llu la f^ o o l
/  \
/  \
\
13C Leucine I
I
/
/
Xx  "C M C
13C Leucine 
Plasma Pool
13C KIC
h 13c o 3-
/ OXIDATIO
h 13c o 3-
(bone, organic acids etc)
1 6 6
Figure 4.3: Outline of rhGH protocol
2 months
5 months
Baseline study 
rhGH
2nd study
randomisation (4 patients)
V
3rd study
167
Figure 4.4 Enrichment of breath and
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Figure 4.8: Pre and post rhGH flux in patients a-h
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Figure 4.10(i): Endocrine changes pre and post
rhGH in patient a
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Figure 4.10(H): Endocrine and leucine changes
pre and post rhGH in patient a
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Figure 4.11 (i): Endocrine changes pre and post
rhGH in patient b
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Figure 4.11(ii): Endocrine and leucine changes
pre and post rhGH in patient b
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Figure 4.12(i): Endocrine changes pre and post
rhGH in patient c
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Figure 4.12(ii): Endocrine and leucine changes
pre and post rhGH in patient c
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Figure 4.13(i): Endocrine changes pre and post
rhGH in patient d
30
25
20
15
10
5
0
-5 pre
INSULIN
ALS
IGF-I SDS 
BP-3 SDS
post
180
Figure 4.13(ii): Endocrine and leucine changes pre
and post rhGH in patient d
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Figure 4.14(i): Endocrine changes pre and post
rhGH in patient e
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Figure 4.14(ii): Endocrine and leucine changes 
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Figure 4.15(i): Endocrine changes pre and post
rhGH in patient f
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Figure 4.15(ii): Endocrine and leucine changes
pre and post rhGH in patient f
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Figure 4.16(i): Endocrine changes pre and post
rhGH in patient g
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Figure 4.16(H): Endocrine and leucine changes
and post rhGH in patient g
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Figure 4.17(i): Endocrine changes pre and post
rhGH in patient h
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Figure 4.17(ii): Endocrine and leucine changes
pre and post rhGH in patient h
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Figure 4.18: Ht SDS Pre and post rhGH 
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Chapter 5
Final discussion and conclusion
192
Discussion
5.1 Principal observations
In this study 30% of children with chronic renal failure (CRF) (glomerular 
filtration rate (GFR) under 40 mls/min/1.73m2) and 30% of children with a 
renal transplant, aged between 2 and 17 years had short stature. This is 
defined as height (Ht) standard deviation score (SDS) < -2 SDS. Short 
stature was also present in children with end stage renal disease 
(ESRD) (150) and affected 50% of those recruited to the study. Of the 
children with CRF, 20% had a delay in their pubertal development, whilst 
26% of those with a transplant had pubertal delay. In the ESRD group 
this figure rose to 30% and dropped to 10% in those with normal GFR. 
The percentage of all with pubertal delay from the children recruited to 
the study was 22%.
The reason for the variation in Ht SDS, allowing for genetic and overt 
environmental factors such as nutrition, is not entirely clear and this study 
was designed to attempt to determine which parameters of clinical ( age, 
renal status, BMI, pubertal status, aetiology of renal failure, duration of 
dialysis/ transplant and dose of steroids) and endocrinological origin
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(IGF-I, IGF-II, IGF bioactivity, IGFBPs, insulin, ALS) were important in 
influencing Ht SDS. As data from healthy children were not available for 
comparison, those with normal renal function but requiring steroids for 
either nephrotic syndrome or vasculitis were used as the constant in the 
statistical analysis and potentially this could be a limiting factor in the 
study (These children were initially recruited to be a control for only the 
transplant group). However these children were on low dose steroids as 
maintenance which all but two received on an alternate day basis and 
this regimen has been associated with minimal systemic side effects 
including growth suppression (59).
Ht SDS can be particularly influenced by inadequate growth during times 
of rapid growth i.e. infancy and puberty. The latter is complicated by the 
variation in age of onset of puberty, particularly with CRF where puberty 
can be delayed and the growth spurt attenuated. However, the majority of 
children in the study were either appropriately prepubertal or in early 
puberty before the growth spurt occurs. Pubertal staging had no 
relationship with Ht SDS.
Growth retardation is most noticeable in children with congenital renal 
disease but aetiology of renal disease had no impact on the Ht SDS of
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the population studied, perhaps because of optimisation of conservative 
management during infancy which influences growth positively (30).
BMI, which is normally used more as an assessment of obesity, can also 
provide information about nutritional status if very low. It however had no 
association with Ht SDS. The BMI SDS of most of the patients was 
above 
-1 SDS.
The level of renal function (CRF, post renal transplant or receiving 
dialysis treatment) of the children related negatively to Ht SDS.
Requiring dialysis therapy had the worst effect on Ht SDS, but 
interestingly this relationship became less detrimental when duration of 
dialysis was taken into account, leaving transplantation as the factor with 
the most negative influence on Ht SDS. Commencing dialysis improves 
the quality of life for the patients with terminal CRF, but increased 
morbidity and growth failure can be noted with prolonged dialysis (40). 
The relationship of transplantation with Ht SDS became more negative 
when use of steroid medication was entered into the multiregression 
analysis. However the dose of steroids used had no effect on Ht SDS, 
perhaps as the children were on low dose treatment. Steroid treatment 
has also been reported by other workers to cause growth retardation(97).
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Surprisingly, transplantation was the only variable of all the clinical factors 
studied that had any correlation with Ht Vel SDS and this was positive. As 
confirmed by other studies, an increase in growth rate is observed with 
improved renal function following transplantation (32).
Age had a negative association with Ht SDS, even though the majority of 
children were prepubertal. Nutritional and endocrine abnormalities 
increase with age, as renal function generally deteriorates and this can 
lead to growth suppression.
Of all the endocrine variables studied, IGF-II surprisingly, and not IGF-I 
(SDS), had the strongest relationship with Ht SDS. The latter lost its 
significance when both IGF-I SDS and IGF-II were added into the best fit 
analysis equation. IGF-II levels increase with decreasing GFR most 
probably secondary to accumulation of the IGFBPs which bind the growth 
factors and decrease the rate of their clearance from the circluation. IGF- 
II has been shown to have an influence on growth in the antenatal period. 
In postnatal life it’s role is more uncertain but low levels can be present 
when GH deficiency occurs (105), and in vitro mitotic effects can be 
observed (109). IGF-I levels can be lowered by IGF-II (121). The children 
in the study had mean IGF-I SDS that were <1 SDS and would be 
considered low in a population with elevated GH and IGFBPs (144, 150).
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Neither IGF bioactivity nor IGFBP -1, -2 or -3 had a relationship with Ht 
SDS. IGF bioactivity depends on levels of IGF-I, and - I I  and those of 
IGFBP-1, -2, and -3. The range within the different groups was wide and 
this would weaken any correlation with Ht SDS. It is also important to 
remember that bioactivity is determined in vitro using cartilage discs and 
may not be an accurate reflection of in vivo events where different tissues 
are involved in the growth process.
Accumulation of IGFBPs would distort relationships with growth observed 
in healthy individuals. In some CRF patients, an association between 
IGFBP-2 and Ht SDS has been shown (107). This was not present in the 
children studied here, partly perhaps because only some children had 
CRF, but also may be because levels are more elevated (comparatively) 
than in the study mentioned previously . IGFBP-3 SDS was greater than 
3 SDS in all three groups, consistent with marked increase in levels. This 
occurs due to decreased clearance of molecular fragments (125).
Acid-labile subunit (ALS) also related significantly to Ht SDS. ALS 
stabilises the binary complex formed between IGF and IGFBP-3, thus 
increasing the half-life of IGFs and thus is involved in growth promotion. 
ALS deficiency results in decreased growth (172) and lower IGF and 
IGFBP-3 levels.
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Recombinant human growth hormone (rhGH) improves growth in children 
with CRF and renal transplants (71, 72, 75). Patients with CRF and those 
on steroid treatment can have reduced lean body mass (LBM) (176, 181, 
221). In order to determine whether LBM is reduced due to increased 
catabolism or decreased synthesis, whole body protein kinetics were 
determined using stable isotopes of carbon (13C) incorporated into 
leucine and bicarbonate. Whilst results (table 4.6 and 4.7, appendix 4.1) 
were comparable to those observed in other studies as shown in table 
4.7 (211), protein turnover and resting energy expenditure (REE) 
appeared to be higher in children with CRF than in those with a transplant 
(this could be not confirmed statistically due to the small number of 
patients in each group), despite the higher BMI and use of steroids in the 
latter group both of which have been associated with increased turnover 
in normal individuals (220, 223). This indicates that the LBM of the 
transplanted group may be lower than that of the CRF children. Use of 
rhGH did not show consistent changes in the children, with increased 
turnover observed in some children only, although median values of flux, 
synthesis and oxidation all increased. For protein deposition to occur 
synthesis has to exceed breakdown (179), but in the present study, 
catabolism exceeded synthesis whilst anthropometric data revealed that 
there was a significant increase in LBM. The inconsistency between the 
two findings highlights the discrepancies that can arise from short term 
observations made in states such as fasting which are not commonly
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encountered in the population being studied but are used in an attempt to 
standardise studies. Observations carried out over a longer period are 
therefore more physiological. Fasting in CRF leads to increased 
catabolism, which is exacerbated by acidosis partly by increased 
resistance to the actions of anabolic hormones such insulin and GH. 
TCO 2 , a measure of acid-base status in the children, correlated 
negatively with insulin and leucine incorporation into protein synthesis. 
Variable resistance to GH, and tolerance to prolonged rhGH use was 
evident from the inconsistent increases in IGF-I SDS, unlike IGFBP-3 
SDS which had risen significantly at 2 months but was slightly lower at 5 
months. The rise in LBM was confirmed by the significant increase in 
REE with use of rhGH, and adipose tissue decreased. The rate of growth 
also increased significantly with use of rhGH although measurement over 
the short term can be unreliable.
Interestingly IGF-II, but not IGF-I, was associated significantly with the 
cross-sectional muscle area, ratio of synthesis to flux, weight and BMI 
before use of rhGH but not after. Thus IGF-II appears to have a 
significant role in anthropometric parameters in children with CRF. This 
has been demonstrated in both the study of the GH-IGF axis and that of 
protein turnover in children with CRF.
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5.2 Therapeutic possibilities for the management 
of the growth of children with CRF and renal 
transplants
5.2.1 Titrated dose of rhGH
Resistance to the actions of hormones in CRF has been clearly 
documented by other studies (137, 138). The degree of this appears to 
vary in patients and thus alters the response to rhGH. Whilst changes in 
height, body fat and LBM are reliable indications of the efficacy of rhGH 
treatment in the long term, measuring IGF-I, IGF-II and IGFBP-3 levels in 
combination (105, 148, 219) might provide more immediate information 
about the appropriateness of the rhGH dose being used. The dose of 
rhGH could then be adjusted to produce the desired response in children. 
However the majority of children with CRF and renal transplants show a 
good response to the recommended dose of 4 iu/m2/day over a 
prolonged period (72). Careful work is required to ensure that any 
increase in dosage would not be associated with either additional 
adverse effects, or increased frequency of those recognised at present 
(slipped femoral epiphyses, hypothyroidism, benign intracranial 
hypertension).
200
5.2.2 Recombinant human IGF-I (rhIGF-l)
IGF-I is produced in response to GH stimulation and mediates the 
majority of its actions (88). Recombinant IGF-I is used in patients with 
severe GH resistance, either due to receptor insensitivity or deficiency (5) 
and improves growth in these individuals. It has also been shown to be 
effective in animal models with CRF (236). In normal adults IGF-I 
appears to improve renal function and size (244), reduces insulin levels 
by direct action on the pancreas (245) and in uremic animals reduces 
cholesterol levels (236).
In children with Laron Syndrome (LS) IGF-I treatment reduces excess 
adipose tissue, lowers serum cholesterol, reduces serum lipoprotein (a), 
increases GFR, induces head growth and increases linear velocity (5).
Isolated use of rhIGF-l in infants with LS is less efficacious than rhGH in 
patients with normal GH receptors (5) as the contribution from the direct 
action of GH on epiphyseal cartilage progenitor cells is absent (99).
Use of rhIGF-l is limited by cost and concerns about side effects including 
suppression of thyroid stimulating hormone (5). Dose related effects 
include papilloedema (5), jaw pain, tachycardia and gingivial hypertrophy
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in patients with ESRF (246). Hypoglycaemia in response to IGF-I therapy 
(245) has not been observed in all studies (246, 247)
At present insufficient information is available to recommend its usage in 
children with CRF.
5.2.3 Combined rhGH and rhIGF-l
The combination of GH and IGF-I in animal studies has a greater effect 
on weight gain and growth than either agent on its own (236, 248). Both 
agents are administered by injection and therefore hypothetically could 
be administered together.
GH increases (219), but IGF-I decreases (246) levels of IGFBP-3, the 
major carrier protein of IGF-I with an important role in increasing the half- 
life of IGF-I (and IGF-II) by decreasing clearance from the circulation 
(100). Combined administration in CRF may thus be beneficial in that 
resistance to the action of GH is overcome by administration of IGF-I, but 
levels of intact IGFBP-3 are increased (248) and it may be possible to 
use lower doses of each so decreasing the risk of potential side effects .
The major benefit of combined GH and IGF-I treatment in patients with 
CRF would potentially be of their differential effects on insulin and 
lipoprotein (Lp) a levels, both of which are raised with GH treatment (81,
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249), but lowered by IGF-I administration (249). Elevated levels of insulin 
and Lp (a) are associated with increased atherosclerosis (250), and 
cardiovascular disease is the commonest cause of morbidity in CRF 
(251).
5.2.4 Oral GH secretagogues
In children, one of the difficulties with rhGH treatment is that it has to be 
administered by injection. Oral agents such as MK-677 that stimulate GH 
release are effective in adults in increasing serum GH concentrations, 
IGF-I levels, fat free mass and energy expenditure (252, 253). In short 
children GH secretagogues increase IGF-I levels and whilst they have a 
synergistic action with GH releasing hormone (GHRH), they are partially 
refractory to inhibitory influences that abolish the actions of GHRH (254). 
Data on long term studies using these secretagogues have not yet been 
published.
Currently rhGH is administered by a single nocturnal injection. However, 
endogenous GH secretion is pulsatile and frequent and there is some 
evidence that the rapidity with which GH levels increase may modulate its 
response (80). In animals intermittent infusion is more effective than 
continuous infusion (255). Theoretically rhGH can be administered in a 
pulsatile manner but this would entail repeated injections, or boluses of 
an infusion under manual operation as no device is available (to the best
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of the author’s knowledge) that can be programmed to administer 
boluses. Using variable release preparations of oral secretagogues, it 
maybe possible to manipulate medication to mimic pulsatility of 
endogenous GH.
5.2.5 IGFBP inhibitors
Elevation of insulin-like growth factor binding proteins (IGFBPs) in CRF 
leads to inhibition of IGF activity as the affinity of the IGFBPs for IGF-I 
and - I I  is greater than that of their receptors (88). Analogues of 
recombinant human IGF-I that bind to the IGFBPs, but do not stimulate 
IGF receptors, in animals models without renal failure, improve bone 
growth and weight gain by displacement of bound endogenous IGF-I 
particularly when given in combination with IGF-I (256). Non-peptide 
molecules based on peptide structures that will specifically bind to only 
one IGFBP (257) and thus displace IGF-I are being considered, and, if 
orally active, will make administration much easier(256).
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5.2.6 Protein intake
Even with adequate caloric intake, LBM in patients with CRF can be 
reduced (181). Studies have demonstrated that in CRF and ESRD
patients, excessive (178) or insufficient protein intake (187) leads to 
inefficient protein turnover with reduced synthesis. Protein restriction, 
particularly with advanced CRF, reduces urea production and may slow 
progression of nephron loss (177). In children protein intake, especially 
of essential amino acids, has to be closely monitored to enable growth, 
and it maybe possible to optimise protein intake by using techniques such 
as DEXA, that provide information on body composition (258), to enable 
accurate assessment of LBM on various protein intakes.
5.2.7 Exercise
Children with CRF and renal transplants probably have lower exercise 
tolerance than their healthy peers due to reduced lean body mass and 
complications such as anaemia and acidosis. However exercise 
increases endogenous GH secretion (259), IGF-I levels (260), and LBM 
(261), which in turn improves BMD (262). In renal patients, individually 
tailored exercise programs maybe of benefit.
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5.2.8 Nutrition
The importance of nutrition in growth is now universally accepted, 
particularly in infants (30, 38). Strict conservative management with close
attention to diet and energy supplements has been effective in preventing 
decreases in Ht SDS (79). Use of overnight nasogastric tube feeds or 
percutaneous gastrostomy feeds if necessary are widely implemented to 
ensure adequate caloric intake (79).
In older patients, especially adults, inadequate nutrition is associated with 
increased morbidity and mortality (153).
5.3 Final Conclusion
Short stature with a Ht SDS £ -2 SDS can be observed in children with 
CRF, post renal transplantation or those with ESRD on dialysis treatment. 
Many factors, both clinical and endocrinological, influence Ht SDS. IGF-II 
was the single most important variable as determined by multiregression 
analysis. Modality of renal treatment, age, duration of dialysis treatment 
and ALS were also significant. Surprisingly IGF-I (SDS) and IGFBPs had
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no significance. The value of rhGH therapy in improving the growth of 
short children with CRF and renal transplants is widely acknowledged. 
Increase in lean body mass is an important consequence of rhGH 
therapy despite the lack of significant alterations in protein kinetics.
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Appendices
Appendix 2.1 Clinical and laboratory features of children with CRF
atient Gender Age Pubertal Diagnosis BMI* GFR TC02 BMISDS Height Weight Ht SDS HtVel HtVel Creat albumin
(yrs) status (kg/m2) (mmol/l) (cm) (cm) SDS (cm/yr) (umol/l) (g/i)
1c f 10.4 1 c 17(50th) 34 23 -0.23 135.2 30.4 -0.68 -0.76 6.5 97 44
2c m 12.0 2 c+vur 15(9th) 17 na -1.32 144.2 31.7 -0.80 -0.04 5.4 na 45
3c m 14.0 3 alports 20(75-91 st) 10 na 0.43 163.9 52.9 0.13 -1.69 7.1 616 38
4c m 11.0 1 c+vur 17(50-75th) 13 20 -0.06 124.0 25.8 -2.99 -2.47 3.3 823 43
5c m 17.0 3 puv 18(25-50th) 25 25 -1.46 142.5 35.8 -4.48 7.60 5.9 706 41
6c f 12.5 1 c 28(98-99.6th) 16 22 2.42 138.1 52.5 -2.09 -2.99 5.2 598 46
7c f 8.8 1 acq 14(2-9th) 20 22 -1.07 112.7 18.4 0.03 -3.86 6.0 167 40
8c m 12.5 2 c 17(25-50th) 18 21 -0.23 133.5 30.8 -2.49 2.46 na 191 45
9c m 14.8 3 puv 22(91-98th) 34 18 1.32 147.6 50.0 -2.44 -0.15 8.4 323 42
10c m 11.7 1 vaters 17(50th) 12 23 -0.13 129.0 28.3 -2.62 -2.20 5.1 542 42
11c m 7.5 1 cyst 15(9-25th) 34 25 -0.54 95.2 13.5 -5.65 -0.64 4.6 119 33
12c m 12 1 arpkd 15(9th) 22 21 -1.41 131.4 26.1 -2.35 0.39 6.8 325 43
13c m 17.0 5 c+vur 23(91 st) 20 17 0.79 172.4 67.4 -0.45 10.86 8.3 503 42
14c m 13.5 4 unknown 16(9th) 28 na -1.30 152.1 37.1 -1.07 -4.10 4.5 476 40
15c m 11.5 1 c 15(9-25th) 29 22 -1.38 139.8 29.2 -0.82 1.48 6.0 289 44
16c f 10.3 1 c 15(9-25th) 16 23 -0.84 134.4 27.9 -0.82 -0.75 4.8 474 44
for key to diagnosis refer to list of abbreviations *centile GFR-mls/min/1.73m2
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Appendix 2.1 (cont) Clinical and laboratory features of children with CRF
Patient Gender Age
(yrs)
Pubertal
status
Diagnosis BMI*
(kg/m2)
BMISDS Height
(cm)
Weight
(cm)
Ht SDS HtVel
SDS
HtVel
(cm/yr)
Creat
(umol/l)
17c m 13.3 2 wilms 17(25-50th) -0.49 150.1 38.9 -0.77 -3.47 9.3 369
18c m 14.3 3 fsgs 20(75-91 st) 0.36 157.0 48.6 -1.00 -3.61 3.0 810
19c m 15.0 3 c+vur 17(25-50th) -1.10 149.5 38.4 -1.65 0.56 10.0 312
20c f 13.8 4 fsgs 19(50-75th) -0.22 167.2 52.4 1.11 -1.54 0.8 617
21c m 11.5 1 arpkd 25(99.6th) 2.31 140.8 48.6 -0.77 2.05 6.4 531
22c m 9.5 1 acq 13(0.4th) -2.36 123.1 20.0 -2.74 2.69 7.2 216
23c f 13.0 4 c+vur 22(91-98th) 1.23 159.6 57.1 0.51 0.09 5.2 153
24c m 16.3 4 c+vur 21 (75-91 st) 0.44 165.0 57.8 -1.16 2.20 4.2 184
25c m 3.3 1 arpkd 15(9th) -0.59 93.2 13.3 -2.24 -3.49 2.7 125
26c m 4.50 1 arpkd 16(50th) 0.11 97.9 15.1 -1.90 -0.98 8.4 na
27c m 4.0 1 puv 17(75-91 st) 0.78 97.4 15.9 -1.46 -1.89 4.9 212
28c f 13.0 1 c+vur 25(98th) 1.79 146.0 52.6 -1.23 -4.14 3.4 185
29c m 7.0 1 puv 19(98th) 2.03 119.7 27.8 0.08 -3.86 6.3 461
30c m 15.5 4 c 19(50-75th) -0.42 175.5 57.7 0.51 na 9.0 228
31c m 12.3 2 c+vur 20(91 st) 0.91 153.5 46.6 0.51 0.60 4.9 167
for key to diagnosis refer to list of abbreviations *centile GFR-mls/min/1.73m2
albumin
(g/i)
37 
44 
44
42 
44
43 
35
38 
35 
30
39 
42
41
42 
42
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Appendix 2.2 Clinical and laboratory features of children with renal transplant
Patient Gender Age Pubertal Diagnosis BMI* BMISDS GFR TC02
Status (kg/m2) (mmol/l)
1t m 10.3 1 c+vur 25.6(99.6) 2.71 81 20
2t m 16.3 1 oto-brach 19.9(25-50) -0.10 60 na
3t m 11.3 1 c 17.2(50-75) 0.10 14 24
4t m 12.0 1 c 20.7(91-98) 0.93 25 21
5t m 17.3 2 c+vur 19.1(25-50) -0.72 70 22
6t m 16.7 3 fsgs 22.3(75-91) 0.72 27 20
7t m 14.1 3 c 25.2(98-99.6) 1.94 7 na
8t f 10.7 1 fsgs 23.4(98-99.6) 1.96 85 25
9t m 16.0 3 fsgs 28.4(98-99.6) 2.32 37 21
10t m 11.3 1 c+vur 26.2(99.6) 2.62 59 21
11t m 14.0 1 puv 24.0(91-98) 1.74 13 21
12t m 13.0 1 c+vur 23.4(91-98) 1.82 33 19
13t m 12.5 1 c 19.4(91) 0.74 16 na
14t m 15.0 4 c 17.4(9) -0.96 23 na
for key to diagnosis refer to list of abbreviations *centile GFR-mls/min/1.73m2
Appendix 2.2(cont) Clinical and laboratory features of children with renal transplant
Patient Height Weight HtSDS HtVel HtVel Creat albumin rransplanSteroids”
(cm) (cm) SDS (cm/yr) (umol/l) (g/l) duration
(month)
1t 141.6 51.3 0.26 -0.35 5.0 85 43 3 0.2
2t 157.1 49.1 -2.32 4.72 12.4 109 39 9 0.2
3t 142.7 35.1 -0.27 4.56 8.2 258 43 24 0.3
4t 129.5 32.9 -2.79 -0.97 4.2 na 44 16+ 0.5
5t 150.7 43.4 -3.56 5.61 0.4 133 42 5+ 1.0
6t 148.0 48.8 -3.67 3.43 10.2 152 41 36 0.2
7t 144.4 52.0 -2.2 -7.32 0 246 43 30 0.2
8t 120.3 33.9 -3.15 -3.48 0 57 42 48 0.3
9t 146.6 61.1 -3.48 -0.46 na 96 47 72 0.2
10t 145.5 55.4 0.12 0.48 5.3 158 40 48 0.2
11t 147.4 52.1 -1.74 -3.52 4.4 78 40 36 0.2
12t 139.6 45.8 -2.01 -2.34 3.4 125 39 36 0.2
13t 146.6 41.8 -0.61 6.92 10.4 318 42 96+ 0.2
14t 154.9 41.8 -1.77 -1.92 5.1 155 41 84 0.2
+ retransplanted *mg/kg/alt da
Appendix 2.2(cont) Clinical and laboratory features of children with renal transplant
Patient Gender Age Pubertal Diagnosis BMI* BMISDS GFR TC02
Status (kg/m2) (mmol/l)
15t m 6.5 1 c 18.3(91-98) 1.66 66 22
16t m 10.3 1 puv 19.5(91-98) 1.27 53 25
17t f 9.0 1 c 24.1 (>99.6) 2.49 62 21
18t f 11.8 1 c 20.6(91-98) 0.96 40 25
19t m 10.0 1 c 19.5(98) 1.34 40 22
20t m 14.5 4 unknown 22.7(98) 1.32 na na
211 m 6.1 1 c 15.8(50) 0.25 76 19
22t m 13.5 2 mesangio 23.3(98-99.6; 1.68 55 22
23t m 12.5 2 puv 18.2(50-75) 0.20 49 21
24t f 10.0 1 c 15.6(25-50) -0.66 48 20
25t m 11.5 1 c 17.9(50-75) 0.36 53 19
26t f 12.5 5 fsgs 17.9(50-75) -0.24 20 23
27t f 13.5 1 fsgs 15.4(9-25) -1.93 28 na
for key to diagnosis refer to list of abbreviations *centile GFR-mls/min/1.73m2
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Appendix 2.2(cont) Clinical and laboratory features of children with renal transplant
Patient Height Weight Ht SDS HtVel
(cm) (cm) SDS
15t 121.0 26.8 0.58 2.62
16t 130.0 32.9 -1.54 1.5
17t 123.7 37.0 -1.66 3.47
18t 135.5 37.8 -1.75 2.24
19t 134.1 35.0 -0.59 4.38
20t 154.7 54.4 -1.29 -5.04
211 108.1 18.5 -1.73 2.86
22t 149.1 51.8 -1.26 0.19
23t 146.0 38.7 -0.71 4.47
24t 134.1 28.1 -0.80 0.46
25t 136.8 33.5 -1.32 0.72
26t 135.4 32.8 -2.30 -5.37
27t 141.1 30.6 -2.34 -2.22
HtVel Creat albumin Transplanl Steroids*
(cm/yr) (umol/l) (g/i) duration
(month)
8.8 76 40 40 0.3
6.2 120 40 72 0.3
8.2 73 43 38 0.2
10.4 67 36 16 0.2
8.3 139 39 na 0.3
3.4 78 37 4 0.2
9.2 62 41 32 0.4
5.4 87 40 36 0.2
8.5 94 41 36 0.3
5.9 151 38 74 0.4
5.5 127 40 72 0.3
2.3 453 42 72 0.2
3.4 127 43 72 0.2
*mg/kg/alt day
Appendix 2.3 Characteristics of children with ESRD
Patient Gender Age Pubertal Diagnosis BMP BMISDS TC02 
(yrs) status (kg/m2) (mmol/l)
1d m 10.8 1 c 22.8(98-99.6) 2.08 25
2d m 14.5 2 puv 17.4(50th) -0.80 26
3d f 7.0 1 cns 17.2(50-75) 0.80 na
4d m 16.8 3 c+vur 15.9(9-25) -2.19 na
5d m 13.0 1 fsgs 14.7(2nd) -2.11 28
6d f 9.0 1 acq 17.7(75-91) 0.59 30
7d f 6.0 1 c 15.9(50th) 0.27 23
8d f 14.3 1 fsgs 18.4(50th) -0.48 na
9d m 2.5 1 c 18.5(91-98) 1.48 na
10d f 12.8 2 c+vur 21.2(91-98) 0.92 na
for key to diagnosis refer to list of abbreviations *centile
Appendix 2.3 (cont) Characteristics of children with ESRD
atient Height
(cm)
Weight
(cm)
Ht SDS HtVel
SDS
HtVel
(cm/yr)
Creat
(umol/l)
albumin
(g/i)
Duration
dialysis
(month)
1d 124.2 35.1 -3.00 -3.15 2.9 598 35 60*
2d 159.5 44.3 -0.86 1.86 11.5 1278 36 12
3d 106.5 19.5 -2.97 -2.54 3.6 na 35 60*
4d 146.7 35.4 -3.79 na na na 33 48
5d 153.8 34.8 0.03 0.12 5.7 1203 39 6
6d 119.6 25.3 -2.14 -1.43 4.4 832 37 72
7d 107.8 18.5 -1.20 -1.60 4.6 586 32 36
8d 158.6 46.4 -0.23 4.44 5.2 850 33 12
9d 87.0 14.0 -0.75 0.42 8.7 600 30 24
10d 136.8 39.7 -2.44 -0.86 7.0 633 35 24
* haemodialysis
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Appendix 2.4 Characteristics of children with normal GFR on steroid treatment
atient Gender Age Pubertal Diagnosis BMI* BMISDS TC02
(yrs) status (kg/m2) (mmol/l)
1n m 13.3 3 ns 24(98-99.6) 1.90 na
2n m 10.8 1 vas 24(98-99.6) 2.32 21
3n m 9.9 1 ns 14(2-9) -1.86 23
4n m 10.0 1 ns 21(98-99.6) -3.47 22
5n m 14.3 3 ns 18(50-75) -0.38 25
6n m 11.2 1 ns 21(98-99.6) 1.61 23
7n f 9.8 1 ns (91-98) 1.43 26
8n f 11.5 1 vas 20(91) 1.00 27
9n f 13.3 2 ns 22(75-91) 1.09 22
10n m 13.5 3 ns 20(75-91) 0.83 30
for key to diagnosis refer to list of abbreviations *centile
Appendix 2.4 (cont) Characteristics of children with normal GFR on steroid treatment
Patient Height Weight HtSDS HtVel HtVel Creat albumin Steroid
(cm) (kg) SDS (cm/yr) (umol/l) (g/i) mg/kg/alt day)
1n 154.2 57.3 -0.41 -1.64 3.0 76 43 0.3
2n 139.8 46.7 -0.60 -4.90 1.6 52 42 0.4*
3n 138.3 26.4 0.09 0.01 5.3 35 36 0.6
4n 146.3 26.4 1.30 -0.78 4.7 65 34 0.3
5n 163.1 48.1 -0.09 -0.79 6.6 71 39 0.2
6n 159.2 53.7 1.53 1.09 5.7 44 39 0.1
7n 132.0 35.9 -0.79 -0.80 4.8 40 34 0.6
8n 145.2 43.2 -0.08 na na 61 33 0.6*
9n 155.3 53.4 0.74 2.60 8.7 44 33 0.6
10n 135.0 37.2 -2.91 -2.99 3.5 56 41 0.5
‘daily steroids
Appendix 2.5 Characteristics of patients in study of effects of rhGH on protein turnover and growth
Patient Age Gender Pubertal GFR Steroid HtSDS HtVel BMI (centile) TC02 albumin Bone age
(yrs) stage (mg/kg) SDS (kg/m2) (mmol/l) (g/i) (yrs)
a(12c) 11.6 m 1 22 na -2.50 1.67 15.1 (9th) 21 43 10
c(9c) 14.8 m 3 34 na -2.44 1.56 21.7(91 -98th) 18 42 12
f(10c) 11.6 m 1 12 na -2.62 -2.73 17.3(50th) 23 42 na
h(8c) 12.5 m 2 18 na -2.49 2.46 17.3(25-50th) 21 45 9.2
j(11c) 7.5 m 1 34 na -5.65 -0.64 14.9(9-25th) 25 35 na
k+(4d) 16.7 m 3 na na -3.79 8.84 15.9(0.4th) 23 33 na
l*(2t) 15.2 m 1 14 na -2.59 1.90 17.0(9-25th) 22 43 na
b*(6t) 17.1 m 3 27 0.2 -3.40 7.12 22.6(75th) 24 41 13
d*(8t) 10.8 f 1 85 0.3 -3.14 -3.71 23.2(98th) 24 42 na
e*(9t) 16.0 m 3 37 0.2 -3.48 -0.46 28.7(98th) 24 47 14
g*(7t) 13.8 m 3 7 0.2 -1.99 -7.06 24.9(98th) 19 43 14
m*(4t) 12.0 m 1 25 0.5 -2.79 -0.97 20.1 (91st) 21 44 na
*Transplant / +ESRD / CRF GFR mls/min/1.73m2
a-m patients in protein turnover study, ( x) patient identity in GH-IGF study.
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Appendix 3.1 Results of children with CRF
Patient IGF-I IGFBP-3 IGF Bioactiv
SDS SDS (U/ml)
1c 0.25 3.44 0.34
2c 1.56 3.69 0.57
3c 1.09 3.85 0.62
4c 0.28 3.77 0.10
5c 0.26 3.65 0.15
6c 2.37 4.27 0.20
7c -1.23 1.96 0.35
8c -2.23 3.22 0.59
9c 0.67 2.94 na
10c -0.15 4.33 0.44
11c 0.19 1.24 0.33
12c 0.3 3.15 0.36
13c 4.72 4.91 0.16
14c 0.81 4.00 0.20
15c -0.55 3.09 0.19
16c 0.62 3.18 0.14
17c 1.06 3.21 0.34
18c 1.36 4.12 0.27
19c 1.69 3.62 0.60
20c na na 0.25
21c 1.57 3.22 0.20
22c na na 0.23
23c 0.92 3.24 2.24
24c 1.36 3.23 0.79
25c -2.54 0.07 0.11
26c -2.02 0.61 0.14
27c 2.19 3.99 0.28
28c -0.42 2.49 0.63
29c 0.07 2.97 0.18
30c 1.74 4.33 0.74
31c -0.13 2.62 0.67
220
IGF-II IGFBP-1
(ng/ml) (ng/ml)
967 29.5
1168 90.9
1284 87.3
1424 66.3
1207 107.0
1414 50.8
896 125.0
1239 93.2
1231 20.2
1299 72.0
374 160.0
1004 96.1
1227 26.6
1085 81.2
1030 160.0
1189 128.0
1684 112.4
1552 92.7
1134 79.1
1302 66.2
1339 66.9
818 131.7
1363 77.1
1369 64.4
370 160.0
250 160.0
1769 160.0
1395 84.7
1316 146.0
1478 74.4
1694 112.3
GHRIA GHH
(mU/l) (ng/l)
1.6 1.0
12.5 5.9
0.9 0.5
5.3 1.5
0.8 0.5
2.0 0.5
12.6 6.5
1.8 0.5
1.4 0.5
22.0 17.2
6.5 2.1
1.2 0.5
7.7 3.5
1.3 0.5
15.4 6.7
70.6 34.4
70.4 32.7
10.2 4.1
8.8 2.6
31.7 15.2
3.6 1.9
7.3 4.8
31.8 17.5
10.6 5.9
13.5 5.9
13.8 7.3
6.2 2.9
0.6 0.5
4.0 1.4
33.4 14.5
13.8 6.2
IGFBP-2
(ng/ml)
1300
760
1600
880
2180
540
1790
838
966
772
1432
900
720
1200
1620
1780
1466
1270
936
1600
74.4
1020
636
1130
1520
1150
1826
1092
1302
890
1050
Appendix 3.1 Results of children with CRF
atient CPEP INSULIN ALS PROTEASE CREAT IGF-lmol IGF-llmol IGFBP-3mol
(pmol/l) (mU/l) (mcg/ml) (%) (umol/l)
1c 33 7.1 48.2 52.8 97 43 126 176
2c 33 10.5 88.0 49.3 na 74 152 187
3c 33 12.6 60.0 57.0 616 61 167 193
4c 630 17.2 35.7 45.1 823 46 185 190
5c 33 15.3 49.0 47.8 706 45 157 185
6c 111 9.5 89.0 66.0 598 111 184 224
7c 33 10.1 18.0 72.0 167 17 116 129
8c 530 10.8 20.8 63.4 191 12 161 167
9c 131 28.1 23.0 26.2 323 57 160 155
10c 514 9.1 26.0 42.6 542 35 169 214
11c 33 7.7 5.8 52.0 119 25 49 89
12c 88 13.5 36.0 39.8 325 44 131 164
13c 123 23.6 90.0 58.2 503 198 160 238
14c 117 10.3 29.0 41.4 476 57 141 200
15c 33 4.2 62.0 62.2 289 134 134 161
16c 33 11.5 40.6 52.3 474 155 155 179
17c 95 22.9 30.6 13.2 369 219 219 166
18c 1263 17.2 38.0 19.5 810 202 202 205
19c 451 10.7 24.0 48.5 312 147 147 184
20c 33 13.2 62.0 57.2 617 169 169 216
21c 235 25.1 71.0 46.8 531 174 174 167
22c 324 10.0 12.5 60.2 216 106 106 108
23c 797 16.5 34.5 46.6 153 177 177 181
24c 800 12.1 30.2 17.4 184 178 178 167
25c 94 20.0 3.1 51.6 125 48 48 51
26c 878 10.4 3.5 30.4 na 33 33 67
27c 48 12.2 34.2 39.5 212 230 230 200
28c 96 13.7 28.0 37.1 185 181 181 150
29c 1041 14.0 24.0 17.3 461 171 171 156
30c 675 20.3 36.9 40.0 228 192 192 214
31c 694 17.7 30.4 27.2 167 220 220 142
Appendix 3.2 Results of children with renal transplant
itient IGF-I IGFBP-3 IGF Bioactiv IGF-II IGFBP-1 IGFBP-2 GHRIA GHHYBI
SDS SDS (U/ml) (ng/ml) (ng/ml) (ng/ml) (mU/l) (ng/i)
1t 1.83 3.49 1.29 1484 45.6 266 1.4 0.5
2t 1.96 3.21 0.59 1299 59.3 1108 1.0 0.5
3t 1.00 3.80 0.62 1569 112.2 606 22.0 9.8
4t 0.73 2.98 0.06 1223 98.9 864 3.7 34.1
5t 0.19 4.12 na 1071 45.1 754 26.7 14.1
6t 0.02 2.59 na 374 65.7 688 1.5 0.5
7t -3.22 3.49 0.11 1300 126.9 866 1.2 0.5
8t -1.27 1.29 1.32 963 71.3 262 1.3 na
9t 0.79 3.26 0.49 1108 12.3 364 1.1 5.0
10t 1.56 3.57 0.84 1393 87.1 1084 27.6 8.3
11t 0.38 2.40 na 1333 90.0 1102 5.4 2.1
12t 0.92 3.26 0.48 1531 163.5 756 2.0 0.5
13t 2.22 5.01 0.73 1880 122.3 2432 1.6 0.7
14t 1.45 4.08 na 1633 114.6 1592 25.8 10.5
15t 1.55 3.43 na 1580 67.7 648 3.2 0.5
16t 0.86 2.95 na 1240 113.0 1014 2.2 0.5
17t 1.33 3.39 na 1400 57.4 412 4.6 1.5
18t 0.85 2.87 2.19 1453 92.0 928 65.6 29.6
19t 1.00 3.86 0.55 1681 135.1 938 2.8 0.5
20t 0.81 4.00 na 1361 47.4 890 1.4 0.5
211 0.36 2.93 na 1404 142.1 1426 24.4 12.8
22t 1.90 3.45 na 1569 57.0 504 9.2 2.9
23t 1.94 3.73 na 1561 94.1 674 5.2 1.4
24t 1.76 2.95 na 1134 21.4 426 28.8 14.6
25t 1.56 3.38 1.10 1435 83.5 1140 1.6 0.5
26t 1.65 4.32 0.13 1310 68.7 672 44.5 22.1
27t 0.52 3.59 0.49 1374 76.7 896 3.2 1.1
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Appendix 3.2 Results of children with renal transplant
Patient
1t
2t
3t
4t
5t
6t
7t
8t
9t
10t
11t
12t
13t
14t
15t
16t
17t
18t
19t
20t
21t
22t
23t
24t
25t
26t
27t
INSULIN ALS PROTEASE CREAT
(mU/l) (mcg/ml) (%) (umol/l)
15.3 34.9 32.8 85
14.4 38.1 19.3 89
14.5 32.4 36.2 59
9.3 25.0 54.6 81
11.4 28.7 50.1 45
5.6 26.8 53.3 38
13.7 24.0 57.8 6
6.6 19.9 66.2 20
35.2 29.1 40.7 54
20.7 33.5 40.3 76
14.0 28.1 39.3 35
5.2 24.9 39.3 50
13.0 39.0 47.0 86
4.3 36.1 49.7 71
8.6 40.4 35.6 70
7.2 28.0 34.3 56
8.6 35.9 30.1 67
7.4 30.0 42.9 59
7.8 34.2 56.8 61
19.7 40.5 29.4 108
4.5 28.0 51.8 38
17.9 44.2 16.1 94
15.7 44.0 18.3 86
27.8 29.1 22.0 83
11.8 32.1 14.9 55
6.6 34.0 55.8 84
4.4 32.1 35.8 53
CPEP
(pmol/i)
751
52
967
397
570
245
1043
67
63
41
50
42
86
49
43
54
39
37
7575
61
20
799
617
1115
880
944
286
223
IGF-lmol IGF-llmol IGFBP-3mol
193
169
204 
159 
139 
49
169 
125 
144 
181 
173 
199 
244 
212
205 
161 
182 
189 
219 
177 
183 
204 
203 
147 
187
170 
179
193
169
204 
159 
139 
49
169 
125 
144 
181 
173 
199 
244 
212
205 
161 
182 
189 
219 
177 
183 
204 
203 
147 
187
170 
179
178
166
191
156
205
140
178
103
168
181
133
168
243
203
176
155
187
165
194
206
154
190
188
169
173
226
196
Appendix 3.3 Results of children with ESRD
Patient IGF-I IGFBP-3 IGF Bioactiv IGF-II
SDS SDS (U/ml) (ng/ml)
1d 0.82 3.38 0.58 1585
2d 1.18 4.78 0.35 1817
3d 1.67 4.91 0.16 1649
4d -0.60 3.29 0.08 1181
5d 1.86 4.68 0.25 1628
6d 1.09 4.21 na 1734
7d 0.76 3.04 0.44 1412
8d 1.06 4.91 0.69 1902
9d 0.08 3.62 na 1431
10d 0.03 3.12 0.23 1208
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IGFBP-1 IGFBP-2 GHRIA 3HHYBRIT
(ng/ml) (ng/ml) (mU/l) (ng/l)
89.2 1874 2.0 0.5
144.1 2448 14.8 7.0
58.2 1164 5.0 1.6
118.0 1154 6.0 2.2
164.2 2124 9.0 3.3
160.0 2808 8.0 2.9
160.0 1818 7.6 1.4
116.2 2530 7.2 1.8
160.0 3882 18.0 9.2
100.6 1050 9.9 3.8
Appendix 3.3 Results of children with ESRD
Patient CPEP INSULIN ALS PROTEASE IGF-lmol IGF-llmol IGFBP-3mol 
(pmol/l) (mU/l) (mcg/ml) (%)
1d 2000 18.7 25.2 15.2 49 206 174
2d 94 7.3 31.5 44.9 59 236 233
3d 2000 43.2 31.6 32.5 70 214 232
4d 355 10.8 24.0 51.7 32 154 169
5d 229 13.9 33.1 41.9 80 212 229
6d 142 6.1 29.8 50.2 60 225 222
7d 94 11.1 27.3 55.4 42 184 173
8d 144 13.5 35.5 23.6 68 247 251
9d 218 12.4 25.5 99.6 41 186 183
10d 375 8.2 20.6 52.3 42 157 176
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Appendix 3.4 Results of children with normal GFR on steroids
Patient IGF-I IGFBP-3 IGF Bioactiv IGF-II IGFBP-1 IGFBP-2 GHRIA GHHYBF
SDS SDS (U/ml) (ng/ml) (ng/ml) (ng/ml) (mU/l) (ng/i)
1n 0.88 2.768 1.18 900 13.3 350 3.3 1.5
2n 1.61 3.028 0.90 860 25.1 324 0.9 0.5
3n 1.55 1.768 0.39 841 65.9 470 0.6 0.5
4n 4.03 1.850 0.40 724 25.5 230 12.3 6.5
5n 2.67 2.945 0.81 1104 35.4 440 13.2 2.6
6n -0.40 2.173 0.67 889 57.9 360 1.2 1.2
7n 1.25 2.890 0.54 1398 21.5 306 14.4 7.0
8n -0.05 1.638 0.43 960 37.7 592 6.8 1.6
9n 1.72 3.360 1.77 1396 19.3 416 3.0 0.8
10n 1.55 2.911 0.87 1287 33.7 604 4.8 1.0
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Appendix 3.4 Results of children with normal GFR on steroids
atient CPEP INSULIN ALS PROTEASE CREAT IGF-lmol IGF-llmol IGFBP-3
(pmol/l) (mU/l) (mcg/ml) (%) (umol/l)
1n 33 13.9 51.5 53.0 76 58 117 148
2n 33 11.0 90.0 49.4 52 73 112 159
3n 33 5.9 49.4 48.0 35 21 109 108
4n 33 7.0 46.0 50.2 65 46 94 111
5n 33 12.1 41.0 63.5 71 96 144 155
6n 33 7.8 48.0 54.3 44 35 116 124
7n 809 24.3 33.9 15.5 40 66 182 166
8n 732 12.2 24.3 53.5 61 39 125 116
9n 1629 55.3 48.2 18.0 44 87 181 186
10n 781 25.0 44.5 17.3 56 70 167 154
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Appendix 4.1 Protein turnover indices and anthropometric data from protein turnover study
Rhgh PATIENT FLUX* SYNTH* oxidation* RQ REE IGFI IGFBP-3 fat muscle
g/kg/day g/kg/day g/kg/day kcal/day SDS SDS mm2 mm2
pre a 6.05 5.45 0.60 0.81 944 -1.28 2.93 954 1642
post a 6.16 5.36 0.80 0.75 1336 -3.32 4.80 770 1910
pre b 3.69 3.25 0.44 0.74 1017 0.02 2.59 3543 3178
post b 4.34 3.81 0.53 0.72 1384 3.29 5.96 2399 3121
pre f 4.89 4.33 0.56 0.78 1118 -0.08 3.14 648 1840
post f 5.28 4.67 0.61 0.73 1135 -0.51 3.21 619 2527
post f 5.31 4.82 0.49 0.68 1423 -0.74 3.43 371 1958
pre e 4.36 3.67 0.69 0.81 1235 0.79 3.26 5700 3363
post e 4.60 3.61 0.66 0.76 1471 2.68 3.63 5717 4578
post e 3.83 3.21 0.62 0.82 1576 2.50 3.76 5717 4578
pre c 4.95 4.44 0.51 0.87 1362 0.67 2.94 1794 4460
post c 4.95 4.40 0.55 0.73 1537 -0.11 3.10 1718 4646
pre g 3.77 3.47 0.30 0.78 960 -0.82 3.19 3160 3251
post g 3.76 3.31 0.45 0.77 1652 8.12 5.14 3650 4005
post g 3.99 3.59 0.40 0.72 1502 3.34 5.89 3566 3242
pre d 4.34 3.55 0.79 0.72 1096 -0.98 1.26 3440 2401
post d 4.24 3.66 0.58 0.87 1404 0.87 2.12 2121 2867
pre h 6.65 6.00 0.66 0.72 1433 -2.23 3.21 788 2181
post h 6.89 6.16 0.73 0.79 1607 0.56 3.54 635 2928
post h 6.20 5.34 0.86 0.80 1509 0.51 3.43 412 2797
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Appendix 4.1 Endocrine parameters from protein turnover study
RhGH PATIENT IGF1 IGFbio IGFII IGFBP-1 IGFBP-2 IGFBP-3 GHRIA CPEP INSULIN ALS CORTISOL
ng/ml U/l ng/ml ng/ml ng/ml ng/ml mU/l pmol/l mU/l mcg/m nmol/l
pre a 142 0.07 1082 165.9 1220 4410 6.8 343 7.6 23.6 353
post a 34.7 0.08 1113 113.4 978 6690 6.0 756 14.5 26.8 123
pre b 292 na 374 65.7 688 4010 1.5 245 5.6 26.8 155
post b 1109 0.51 719 43.5 494 8050 7.1 720 12.3 33.9 263
pre f 250 0.25 1230 94.7 1028 4670 1.0 589 10.5 20.9 232
post f 150 0.31 1290 84.2 1086 4750 3.1 393 7.7 20.6 185
post f 182 0.33 1351 71.0 1264 5020 8.0 469 11.2 22.0 209
pre e 416 0.49 1108 12.3 364 4810 1.1 63 35.2 29.1 13
post e 894 0.84 868 5.7 402 5260 14.5 1027 55.6 30.8 54
post e 836 0.74 970 6.7 410 5410 9.9 1340 114.7 29.9 92
pre c 381 na 1231 20.2 966 4420 1.4 131 28.1 23.0 178
post c 275 0.89 1033 47.7 790 4620 3.3 585 17.6 24.0 403
pre 9 169 0.06 1344 148.3 1180 4730 3.7 859 8.2 25.0 293
post g 894 0.13 1376 55.9 1170 7090 14.9 1382 29.3 37.6 108
post g 1130 0.10 1304 64.7 1082 7970 14.4 556 34.9 43.0 112
pre d 179 0.44 971 64.7 390 2920 0.5 134 9.3 18.6 80
post d 456 na 1217 96.1 310 3860 11.6 67 7.3 24.2 196
pre h 95 0.59 1239 93.2 838 4760 1.8 530 10.8 20.8 282
post h 383 0.55 1191 93.7 1164 5150 5.1 630 20.4 30.8 439
post h 372 na 1251 84.3 842 5010 1.8 319 8.5 31.2 281
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